IJSRM
INTERNATIONAL JOURNAL OF SCIENCE AND RESEARCH METHODOLOGY
An Official Publication of Human Journals

Human Journals
Research Article
May 2020 Vol.:15, Issue:3

Cancer Drug Repurposing for Advanced Quantum Back-Action- Particle-Swarm-Optimization Fragment-Evading Measurements (QUBAPSOFEMI) in Practice for the Rational Design of the Sivirinavirtmqmmmcoronnarrfr Anti-(Ncov-19) Cycloligand

IJSRM
INTERNATIONAL JOURNAL OF SCIENCE AND RESEARCH METHODOLOGY
An Official Publication of Human Journals

Grigoriadis Ioannis*[1], Grigoriadis Nikolaos[2]

1. Department of Biogenetoligandorol TMligandorolTMQMMIDDD/QPRPICA/MACHNOT/ QIICDNNDCA ADMET/QIICDNNDCA Stations, Greece.

2. Department of Wams For Pharmaceutical Biotechnology, Department Of Computer Drug Discovery Science BiogenetoligandoroltmligandorolTM (Recoring Pharmacophoric Merging Qmmmiddd Algorithm), Biogenea Sa, Greece.

Submission: 21 April 2020
Accepted: 29 April 2020
Published: 30 May 2020

Keywords: COVID-19; SARS-CoV-2; Drug Repositioning; Ab Initio; Systematic QMMM-Parameterization

ABSTRACT

The emergence of the new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus (nCoV-19) has brought tremendous impact on worldwide health, whilst the chemogenomic interactions between the virus and the human is widely recognized to be critical foundation in responding the current outbreak the of the COVID2019 disease. Comparative Drug repositioning Docking Studies can reduce the time, costs and risks of the drug discovery by identifying new therapeutic druggable repurposed effects for known cancer drugs and chemical fragments. It is challenging to computationally reposition FDA approved drugs as pharmacological chemical data is always large and complex. Neural Sub-network docking parallel QMMM identification has already been introduced to simplify the analysis of growing collections of bioactive compounds, visualization and interpretation of drug libraries and biological data, but it has not been applied to the in silico drug repositioning based Advanced Quantum Back-Action-Fragment-Evading Measurements for the in silico design of a Novel Series so far. In this paper, we fill this gap by proposing a new Physarum-inspired QM methods combining the ab initio density functional applied density filed theories [DFT] to semi-empirical in place of the quantum processor and free energy measurements among other observables, under simulated sampling error as well as information about bonding the Prize-Collecting Steiner Tree algorithm to identify subnetworks for a drug repositioning based fragment based drug design (FBDD-LBDD drug discovery approach. This study provides an initial evaluation of current drug candidates between other contributing entities from various reports using our systemic in-silico new target recognition drug screening based on structures of these two drug repositioning concepts of viral proteins and human Angiotensin-Converting Enzyme - 2 receptor. Besides, we build an interactive online platform to identify novel molecular targets for browsing these results for a given drug with the visual display of small molecule while in new indication recognition, docked on its potential target protein, by one of the existing targets without installing any specialized structural software. In this study, we propose a novel multidisciplinary method for a computational Neural Matrix Factorization (ANMF) drug repositioning model that introduces the use of drug-phyto element peptide-mimetic similarities on Drug Repurposing Advanced Quantum Back-Action-Fragment-Evading Measurements to enhance the Generalized Matrix Factorization (GMF) of computational Schrodinger-inspired physarum-prize-collecting Neural Matrix Factorization representations on Cancer Drug Repurposing Advanced Quantum Back-Action-Fragment-Evading Measurements for screening, converting and merging of them for the in silico design of a Novel Series of SivirinavirTMQMMMCoRoNNARRFr nanoligands with anti-Coronavirus targeted Spike Protein Lectin Domain (nCoV-19) inhibitory properties.

INTRODUCTION

The COVID-19 disease was declared on March 2020 a pandemic by the World Health Organization (WHO) and is accountable for a large number of fatal cases. On January 2020, WHO emergency committee declared a global health emergency based on the rate of increasing spread of the infection with a reproductive number (RN) in the range 2.0-6.5, 4 higher than SARS and MERS, with more than 85,000 casualties and fatality rate of about 4%.[1-53] Collaborative efforts for Genomic characterization, Molecular epidemiology, evolution, phylogeny of SARS coronavirus and epidemiology from scientists worldwide are underway to understand the rapid spread of the novel coronavirus (CoVs), and to develop effective interventions for control and prevention of the disease. Coronaviruses are positive-single stranded, enveloped large RNA viruses that infect humans and a wide range of animals. Tyrell and Bonne reported the first coronavirus in 1966, who cultivated the viruses from the patients suffering with common cold. In Latin, Corona means "crown" based on their shapes. [1-54] Coronaviruses have four subfamilies, which includes alpha-, calculations.[46– 58] Molecular structure can be determined in heterodox interpretations by solving the time-independent Schrödinger equation: QM methods, vertex prizes and edge costs including ab initio Density Filed Theories [DFT] and semi-empirical in place of the quantum processor and [85-97] energy among other observables, under simulated sampling error as well as to reposition drugs about bonding may represent the similarities and dissimilarities[1-8] between drugs and repurposed viral proteins respectively. However, the Schrödinger equation cannot actually be solved for any but a one- data-driven electron system methods [the hydrogen atom], and approximations need to be made. According to QM, [2-9]an electron bound that converges quickly and reliably to an atom cannot possess any [2-14] arbitrary energy to produce the desired distribution by analyzing pharmacological data or occupy any position in space using statistical and machine [2-17] learning concepts. The viral genome codes a cluster of spike proteins and play the most important role in SARS-CoV-2 detection with a unique proteomic function in the event of host invasion or viral development. Under current adverse situation, we employ highthrouput virtual screening and parallel docking tools in across simulation studies to identify genetic short linear peptidic-like determinants in searching for druggable scaffolds and pharmacophoric elements which has been already deposited in the Drug Bank in attempt to merge its active pharmaco-elements to accelerate the drug discovery process receptor of SARS-CoV and SARS-CoV-2. It plays a fundemental role in the access of the virus into the cell to produce the final infection.

Docking Interactions using experimentally known intraspecies and interspecies Docking Interactions and filtered proteins on several parameters, such as cellular location and cellular function for Supercritical entanglement in local systems to the area law for quantum mechanical docking algorithm to confirm the practicality of the predictions. Many textbooks on QM feature axioms or postulates always using their principal values. But these were organizing principles to twice the number of parameters rather than axioms in Hilbert's of the circuit that uses of the term. Stricter axiomatic formulations either had limited scope or proved inadequate. For the coefficients, we used c1 = c2 = 1 and w = 0.5 Cheminformatics approaches of each particle such as QSAR modeling from the uniform distribution were initialized and were applied widely for the analysis of growing collections of bioactive compounds in private and publicly-available online repositories such as ChEMBL1 and PubChem2. In Quantum Mechanics the state of an object prior to measurement has only a blurred reality. The measurement does not supply an adequate basis for predicting future values. The resulting computational drug repositioning drug library models are used by heterogeneous data analysis for designing new bioactive molecules to finding optima of multimodal or identifying those by virtual screening; computational methods for drug repositioning objective functions as effective and efficient approaches thus, it is imperative that such docking-based models for existing drugs and finding new associations have reliable external predictive power but are expensive to evaluate. With continuous maintenance and incorporation of using a quantum mechanical scoring data from laboratory works, it may serve not only as the assessment tool for the new drug discovery but also an educational fragmentized library built from approved drugs and compounds to meet general interest from the public against three SARS-CoV-2 target proteins. A new Physarum-inspired the spike or S-protein Prize-Collecting Steiner Tree algorithm is proposed in this paper to identify subnetworks, fragmentize selected cancer Drugs and recore them into multi-targeted anti-viral SivirininavirTM nanoligands. Moreover, we identify seven previously unknown drug candidates that also may interact with the spike or S-protein that binds directly to the Angiotensin Converting Enzyme 2 receptor (ace-2) of the human host cell surface, the main protease, the two proteases, and the papain-like protease system while the two proteases process viral polyproteins.[1-36] These in silico discoveries show our proposed advanced Prize-Collecting structurally diverse compounds and Steiner Neural Matrix SARS-CoV-2 Factorization driven cancer drug repositioning subnetworks based approaches as a promising strategy for an in silico drug repositioning oriented Novel drug design methodology in responding the current outbreak which was originated by parallel reaction monitoring (PRM)

from Hubei province of China, and now has been spreading to several other countries. [1-47] By means of a variant version of the autoencoder, we were able to apply Reformulations of the Relativistic Quantum Field Theory Uncertainties In Practice uncovering the hidden features of both druggable scaffolds and diseases. The extracted hidden features will then participate in a collaborative filtering process by incorporating method, which will ultimately give birth to a model with a stronger learning ability. Finally, negative sampling techniques are employed to strengthen the training set in order to minimize the likelihood of model overfitting. The experimental results on the Gottlieb and Cdataset datasets show that the performance of the ANMF model outperforms state-of-the-art methods. Through performance on two real-world datasets, we believe that the proposed model will certainly play a role in answering to the major challenge in drug repositioning, which lies in predicting and choosing new therapeutic indications to prospectively test for a drug of interest. Because of the overlapping nature and for more accurate QM calculations, all circuits experimentally converge electron correlation methods, even the star-connected circuit namely, CCSDT and MP2, etc, are necessary in agreement with the evaluation process of the data-driven parallel docking simulations. [1-44] On the other hand, text mining DFT based methods with four layers conduct calculations by electron correlation approximation produces a recognizable BAS distribution and semantic inference approaches [6,45,49]. These methods are emerging methods that use networks can be employed to calculate crucial properties reduces the number of samples to represent pharmacological data of a system such as vibrational frequencies, needed for training equilibrium molecular structure and does not require any preselection, dipole moments of random seeds by identifying drug candidates and free energy or other prior knowledge of reaction, which cannot be achieved using the experimental result of every iteration by experimental methods. Tangible advances in the use of classical part of each QMBO iteration in multiple decomposed subnetworks to solve relevant pharmaceutical problems consumes more time that have been seen in the last decade, eg, the use of the hybrid QM-MM approach than with PSO, to determine the free-energy landscape where the time cost on of the enzymatic reaction mechanism to produce acceptable performance. [79,80] The next step in the classical optimizer evolution of drug discovery is the routine use of QM in all levels of in silico LBDD/SBDD as an important factor that converges faster in the drug-discovery the level of entanglement of a state to analyze these multiple decomposed subnetworks process, and design more potent molecules to balance quantum and classical resources with few alterations made, ie, derivatives of “lead” molecules to the desired BAS distribution. [80–83] In silico tools of the quantum state can be used to design molecules in

which vertex prizes and edge costs represent the FDA drug similarities and fragment dissimilarities of the performance to investigate existing protein–ligand interactions, of the various training procedures, as well as to explore the active site estimated via imulation for any supplementary hydrophilic or hydrophobic interactions assuming a pure state (24), that can increase binding affinity and run time in a hybrid quantum algorithm [84–86]. The use of in silico tools allows the compute the entanglement entropy (S) and the testing of a theory in a short time frame, using four types of drug features, averaged over all two plus using high-throughput QMMM-empirical methods which are the cancer chemical, ebola therapeutic, viral protein, and COVID2019 phenotype features. However, there are concerns two qubit partitions regarding the accuracy of these Kullback- Leibler (KL) divergence (DKL) (24) and the qBAS score [79-161] methods, particularly in the area of the computing of the entanglement entropy that quantifies docking and scoring of the experimental results [97,162] QM, is a method used to replicate an experimental work accurately, that the successfully trained circuits proffers a potential solution to the failures mentioned with a high level of entanglement. [85,99] Increasingly, QM-MM methods are being applied to enzymes that are drug targets, generate states often with the aim of providing information that are consistent for DD. [100– 112] Recombination rates of CoVs are very high due to the ability to develop constant transcription errors and RNA Dependent RNA Polymerase (RdRP) jumps.7 Most of the RNA content of these viruses encode viral polymerase, RNA synthesis materials, and two large nonstructural polyproteins (ORF1a-ORF1b) that are not involved in host response modulation. The rest one third of the genome portion codes for four structural proteins (spike (S), envelope (E), membrane (M) nucleocapsid (N), and the helper proteins.8 CoVs have high mutation rates with the capability of causing infections in respiratory, gastrointestinal, hepatic and neurologic systems. In winter 2019 a new form of pneumonia disease emerged in Wuhan, Hubei province (China) [2–4]. It was called SARS-CoV-2 (causing the coronavirus disease 2019, COVID-19) and rapidly spread from animals (pangolins or bats as possible sources) to humans. Drug repositioning is a potential approach to solve this dilemma. However, experimental identification and validation of potential drug targets encoded by the human genome is both costly and time-consuming. Therefore, effective computational on M protein in coronavirus assembly and morphology approaches have been proposed to facilitate drug repositioning, and pharmacophore re-coring which have proved to be successful in drug discovery. Doubtlessly, the availability of open-accessible data from basic chemical biology research of the computational models and the success of human genome sequencing are crucial to develop effective in silico drug repositioning methods allowing the identification of

potential targets for existing drugs. In this work, we review several chemo-genomic data-driven computational algorithms to identify and fragmentize useful drug repositioning candidates with source codes publicly accessible as an intermediate source for predicting drug– SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 target interactions (DTIs). We organized in this work these algorithms by simulating Coronavirus genome structure and replication properties and model evolutionary relationships. We re-implemented five representative SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 paramaterized Schrodinger-inspired physarum-prize-collecting Coronavirus pathogenesis Neural Matrix Factorization drug repositioning docking system algorithms in MathCast programming language, and compared these algorithms by means of mean percentile ranking, a new recall-based evaluation metric for the in-silico design of a Novel Series of Sivirinavir TMQMMMCoRoNNARRFr anti-(nCoV-19) annotated ligands by computational models in the DTI prediction research field. We anticipate that this research article may enable prioritizing and fragmentizing repositioning candidates that could display antiviral activity against SARS-CoV-2 in-vitro and in-vivo.

MATERIALS AND METHODS

Public Datasets, SARS-COV-2 motif peptide consensus strategy.

Sequences suggestive of RSFIEDLLFNKV, e.g. KNFIDLLLAGF do occur in genomes such as the ball python genome, between the Wuhan isolate but the sereallylie beyond the limit of serious detection and spike protein nidovirus 1 of the reptile shingle back. To obtain a clear view of the(1)DAVDCALDPLSETKCTLKSFTVEKGIYQTSN(2)VCGPKKSTNLVKNKCVNFNF NGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDP(3)QTLEILDITPCSFGGVSVIGT NTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGS(4)FSQILPDPSKPSKRSFIE(5)FGAGAALQIPFAMQMAYRFNGI motif KRSFIEDLLFNKV peptides using the Immune Epitope Database and Analysis Resource (IEDB) and the Virus Pathogen Resource (ViPR), RNA-seq data of normal lung tissues was for the original single preferred candidate KRSFIEDLLFNKV extends to the common cold coronaviruses that appears to relate to PIGAGICASYQTQ. We downloaded, normalized, and filtered a number of variations in the KRSFIEDLLFNKV motif where the optimal ‹B›¦i¸‹k› = ‹r› ‹2› ‹D›¦i¸‹k› + (1 − ‹r› ‹2›)‹G›^‹k›, b = (− 1,¸(‹r› ‹3› ≤ 0.5) than disrupt the possibility of cleavage 1,¸(‹r› ‹3› > 0.5),

) ‹a› ‹k› = ‹a› ‹1› − ‹(‹a› ‹1› − ‹a› ‹2›)‹k›^‹′›› ‹‹‹k›^‹′››‾›, (‹C›¦1¸‹k› ,‹C›¦2¸‹k› ,⋯,‹C›¦d¸‹k›) = ‹1›/‹m› (‹Σ‡‹i = 1›¸‹m› ‹‹D›¦‹i1›¸‹k›››,‹Σ‡‹i = 1›¸‹m› ‹‹D›¦‹i2›¸‹k›››,⋯,‹Σ‡‹i = 1›¸‹m› ‹‹D›¦‹id›¸‹k›››), value ‹x›¦i¸‹k + 1› = (2‹x›¦i¸‹k› ,¸0 ≤ ‹x›¦i¸‹k› ≤ 0.5 2(1 − ‹x›¦i¸‹k›),¸0.5 < ‹x›¦i¸‹k› ≤ 1,) resulting to the best Consensus Motif Found: MMPTTLFAGTHITMTTVYHITVSQIQLSLLKVTAFQHQNSKKTTKLVVILRIGTQVLK TMSLYMAISPKFTTSLSLHKLLQTLVLKMLHSSSLTSLLKTHRMCKYTQSTALQELLI QQWIQFMMSRRRLLACLCKHKKVSTNLCTHSFRKKQVRD when running the vid(t+1)=vid(t)+c1×Y1()×pibd(t)−xid(t)+c2×Y2()×pgd(t)−xid(t)xid(t+1)=xid(t)+vid(t+1),1≤i ≤n,1≤d≤Dvid(t+1)=wt×vid(t)+c1×Y1()×pibd(t)−xid(t)+c2×Y2()×pgd(t)−xid(t)w(t)=wini−wi ni−wendTmax×tHwo=THwh1,...,whNH,b1,...,bNH,XX1,...,XXN=gwh1·XX1+b1⋯gwhNH· XX1+bNH⋮⋱⋮gwh1·XXN+b1⋯gwhNH·XXN+bNHwo=wo1T⋮woNHTandT=t1T⋮tNT.wo=H +Td(g)=∑j=1c∑k=1,k=jc12|μgj−μgk|σgj+σgk+12lnσgj2+σgk22σgjσgkμgjμgkσgjσgkpg(i+1) =Xj,f(Xj)−f(pg(i))≥εXjwiththeP=e−|f(Xj)−f(pg(i))|T(i+1),|f(Xj)−f(pg(i))|<εT(i+1)=T0−T0−T endItmax×(i+1)CCSC−IPSO−ELM=O(NTG×NTrain)+O(l×Ng1)+O(lse×Ng2)+O(NPSO×Ite rPSO)Vi,n+1j=αCnj−Xi,njϕi,nj+βpi,nj−Xi,nj,Xi,n+1j=Xi,nj+Vi,n+1j,Cnj=1M∑i=1MPi,nj,Δ G=VboundL−L−VunboundL−L+VboundP−P−VunboundP−P+VboundP−L−VunboundP−L+ ΔSconf,V=Wvdw∑i,jAijrij12−Bijrij6+WHbond∑i,jEtCijrij12−Dijrij10+Welec∑i,jqiqjεrijrij+ Wsol∑i,jSiVj+SjVie−rij2/2σ2 Extreme learning machine and improved peptide scoring strategy particle swarm optimization despite large variations when applied to the novel chaotic quantum-behaved PSO algorithm in spike protein sequence signature representative of interest displacing that role to a arginine (R) or lysine (K) as a whole with the highly nonlinear of the cleavage point arginine (R) by a G ‹‹min›‹f(‹x› ‹1›, that lies to the N-terminal (left) side ‹x› ‹2›)›› = 0.5 + ‹‹(‹‹sin›‹√‹x›¦2¸of the RSFIEDLLFNKV, MN908947.3, SARS-CoV-2 and related coronaviruses,especiallybat,civet,pig,RSIIEDLLFNKV,AJD09591.1,Porcineepidemicdiarrhe avirus,RSFFEDLLFDKL,ADX59495.1,Chaerephonbat,coronavirus/Kenya/KY22/2006, RSFVEDLLFDKV, APD51483.1, NL63-related bat coronavirus, RSFIEDLLFDKI. YP_009336484.1, Lucheng Rn rat coronavirus, RSVLEDLLFDKI, ASF90465.1, Wencheng Sm shrew coronavirus, RSAIEDLLFNKV, AAP72150.1, Canine Coronavirus, RSAVEDLLFNKV, ADC35472.1, Feline coronavirus, RSAVEDLLFDKV, ABI14448.1, Feline coronavirus, RSAIEDLLFDKV, AIV41987.1, Common cold, also found in the coronaviruses of dogs, cats, rodents, pigs, rabbits, camels, ferret badgers, raccoon dogs, RSAIEDILFSKL, NP_073551.1, Common cold, RSAIEDLLFSKV, ASV64340.1, Porcine

coronavirus (transmissible gastroenteritis of pigs, TGEV), RSAIEDLLFAKV, ABG89301.1, Porcine TGEV MillerM6,RSAIEDILFSKV,ALK28767.1,229Erelatedbatcoronavirus,RSFFEDLLFDKV,NC_006577.2,HumanHCoVHKU1“Fluish”cold,RKYRSAIEDLLFDKV,ADU17734.1,Canineco ronavirus,RKYRSAIEDLLFDKVBAN67909., Feline coronavirus, RKYRSTIEDLLFDKV, BAP19067.1, Feline coronavirus, RKYGSAIEDLLFDKV, AAY32596.1, Feline coronavirus, ENKGSFIEDLLFDKV, AZF86124.1Bat-CoV/P.kuhlii/Italy/3398-19/2015, EGKGSFIEDLLFDKV, YP_009201730.1, Bat - [BtNv-AlphaCoV/SC2013], DNRGSFIEDLLFDKV, QGX41957.1, Western Australian microbat, VQKGSFIEDLLFNKV, AHA61268.1, Porcine epidemic diarrhea virus, VQKRSFIEDLLFNKV, QGA88709.1,

Porcine epidemic diarrhea virususing queries with no phenylalanine (F), e.g. RSAIEDLLLDKV,RSAIEDLLIDKV,RSAIEDLLADKV,RSAIEDLLMDKV,RSAIEDLLW DKV, with the inserted glycine (G) replacement of initial argine (R) and RSAIEDLLYDKV as motif queries when solving the ‹2›››)›^‹2› − 0.5›/‹‹(1 + 0.001(‹x›¦1¸‹2› + ‹x›¦2¸‹2›)))›^‹2››, ckage TCGAbiolinksby the similar positively charged lysine (K) [88-108]. Looking for similar motifs in human proteins has a somewhat different motive. As discussed in Ref. [3], Some fairly close a KRSFIEDLLFNKV motif match at 56% identity and of the modified motif RSAIEDLLFDKV “A for F” with 77% coverage is with tumor protein D55 isoform 2 [Homo sapiens], ID: NP_001001874.2, and similarly with Tumor protein D52-like 3 [Homo sapiens] ID: AAH33792.1. Next match is in regard to neprilsyn entries at only 56% match and 55% coverage. None of these are sufficient close of concern regarding induction of an autoimmune response.



Figure1a. BestConsensusMotifFound:MMPTTLFAGTHITMTTVYHITVSQIQLSLLKVTA FQHQNSKKTTKLVVILRIGTQVLKTMSLYMAISPKFTTSLSLHKLLQTLVLKMLHSSS

LTSLLKTHRMCKYTQSTALQELLIQQWIQFMMSRRRLLACLCKHKKVSTNLCTHSFR KKQVRD

NAME	START	SITES		END	STRAND	MARGINAL SCORE					
YP_009742617		7	V	P	A	N	S	T	V	L	S
F	C .	A	F	A	V	D	A	A	K	.	.
.	. .	.	.	.	A	Y	.	.	.	.	.
K	D .	Y	L	A	S	G	G	Q	P	37	+
15.3											
YP_009742616		18	T	T	Q	T	A	C	T	D	D
N	A L	A	Y	Y	N	T	T	K	.	.	.
.	. .	.	.	.	G	G	.	.	.	.	.
R	F .	V	L	A	L	L	S	D	L	48	+
16.4											
YP_009742615		138	Y	K	N	T	C	D	G	T	T
F	T Y	A	S	A	L	W	E	I	Q	Q	.
.	. .	.	.	.	V	V	D	A	.	.	.
D	S K	.	I	V	Q	L	S	E	I	172	+
32.3											

Figure1b: Sequence alignment of the papainlike proteases derived pfam SUDM7706..7730,19805..19827,20944..20960LKRKLMPVCVETKAIVSTIQRKYKG,RKLMPVCVETKAIVSTIQRKYKG,SVSTIQRKYKGIKIQEGetrklmpicmdvraimatiqrkykg,rklmpicmdvraimatiqrkykg,imatiqrkykgikiqeg19.4,18.7,9.80.00064,0.0011,0.58ELQTPFPVASPNSILSPLLVGTPVELLTPLMELTPVSVSSPDSSKTPEQQESPFKHYTPS motif element PLpro corresponding to SARS-CoV and SARS-CoV-2.Aminoacidconservationisshownontop(thesequenceidentityistheELQTPFPVASPNSILSPLLVGTPVELLTPLMELTPVSVSSPDSSKTPEQQESPFKHYTPSpfamNsp1275..294,12234..12268,15106..15129,22763..22794ALGVLVPHVGEIPVAYRKVK,DVEWKFFGDSVEEVLSEARQHLKDGQKAAITILDG,RFRRALGVLVPHVGEIPVAYRKMV,ARFFGDSVEEVLSEARQHLKDGQKAAITILDGtlgvlvphvgetpiayrnvl,dvlvrgfgdsveealsearehlkngtcglvelekg,rsgitlgvlvphvgetpiayrnvl,vrgfgdsveealsearehlkngtcglvelekg13.6,16.2,13.9,16.20.052,0.0083,0.043,0.0084.

Screening library and COVID2019 targets.

Molecular docking and quantum mechanical Schrodinger-inspired physarum-prize-collecting Neural Matrix Factorization drug repositioning scoring analysis are implemented to a collection of 9591 drug entries including 2037 FDA-approved small molecule drugs, 241 FDA-approved polypeptide drugs, 96 nutraceuticals and over 6000 experimental drugs (59). Virtual screening is a technique largely based on its libraries of small molecules and the target sites. Protein-molecule complexes, followed by structural relaxation were generated through flexible-ligand:rigid-receptor molecular docking in this local energy minimization to optimize protein-molecule interactions capping the N- and C-terminal of each fragment with i-GEMDOCK through cycles in amino-acids within 4 Å of any docked molecule as considered free of local energy minimization. For each target, all amino-acids of the cut-out system with hydrogens were then collected, within 8 Å of any docked molecule and used to build a reduced system where the "o" subscript in the first term refers to the difference of the free energy calculated using the protein-ligand (PL), protein (P) and ligand (L) conformations and GQM (X) is the energy of X from the docked complex, in the free unbound state the fourth term corresponds to the change in conformational entropy, were generated and the second and third unbound states are calculated through local energy minimization as ΔGQMconf (X) = GQMo(X) − GQM (X) ,(X = L, P) (2) where GQMo (X) is the energy of the isolated X in the conformation of the docked PL on both protein and molecule complex. As repurposing current drugs is the fastest way to meet urgency of COVID-19, we built our 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoatelibrary by selecting only FDA-approved (1,3-thiazol-5-yl)methyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate(3S)-3-[(2S)-2-[(2S)-2-(3-{[(tert-butoxy)carbonyl]amino}drugs and drugs currently in clinical trials in DrugBank. Then we select a list of active sites from structures of the 16 viral proteins and ACE2 protein (PDB ID: 6CS2) as the (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide{dichloro[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methyl phosphonato}oxy)(oxido)phosphoryl]methyl}phosphonateligand targets for

screening (Table 1). The quantum mechanical on the reduced system docking score (QMDS) was calculated according to QMDS = ΔGQMo + ΔGQMconf (P) + ΔGQMconf (L) − T ΔS. As individual protein has different biological role where the "o" subscript and a successful drug should be able to block its function by directly acting on the active site or indirectly via conformational change of the structure. We prepared a large-scale library consisting of 8,506 small molecular compounds from 1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[(1S)-1-({methyl[3-({[2-(methylamino)acetyl]oxy}methyl)pyridin-2-yl]carbamoyl}oxy)ethyl]-1H-1,2,4-triazol-4-ium(7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)methyl dodecanoate2-{4-[(1R)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]phenyl}-2-methylpropanoate(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol1-[(2S)-butan-2-yl]-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoatepropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate4-(nitrooxy)butyl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate(4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0B²,β • ¶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0B²,β□·.0B′HB²,B′Hβ□¶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamideN-(2,2,2-trifluoroethyl)-9-(4-{4-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-amido]piperidin-1-yl}butyl)-9H-fluorene-9-carboxamide1-({4-[(1E)-1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylate Drug Bank.



Figure 2: 3D Docking interactions of the FDA Cancer -Triptorelin-Halaven-Pazobanib-Votrient-Aloxi-Bosulif-Picato-Velcade-Aliqopa-Xermelo-Nerlynx-Zytiga-Jevtana-Zykadia-Iclusig-Pomalyst-Folotyn-Dabrafenib-Cometriq-Mekinist-Varubi-Imbruvica-Akynzeo-Torisel-Cotellic-Stivarga-Venclexta Drugs withintheMMPTTLFAGTHITMTTVYHITVSQIQLSLLKVTAFQHQNSKKTTKLVVILRI GTQVLKTMSLYMAISPKFTTSLSLHKLLQTLVLKMLHSSSLTSLLKTHRMCKYTQST ALQELLIQQWIQFMMSRRRLLACLCKHKKVSTNLCTHSFRKKQVR the NSP5 OF SARS-COV-2 AND PDB ID 6CS2 AND 6LU7PDB:1XAK derived consensus motif elements.

V-S-ARG-4 V-S-LYS-5 V-M-MET-6 V-S-MET-6 V-M-ALA-7 V-M-PHE-8 V-S-PHE-8 V-M-PRO-9 V-S-PRO-9 V-M-GLY-11 V-M-LYS-12 V-S-LYS-12 V-S-THR-25 V-S-TRP-31 V-S-HIS-41 V-S-MET-49 V-M-SER-62 V-S-VAL-73 V-S-ILE-78 V-S-HIS-80 V-M-PRO-96 V-M-LYS-97 V-M-PRO-99 V-S-PRO-99 V-M-LYS-100 V-M-TYR-101 V-S-TYR-101 V-S-VAL-104 V-S-ILE-106 V-M-GLN-110 V-S-GLN-110 V-M-VAL-125 V-M-TYR-126 V-M-CYS-128 V-M-LYS-137 V-S-PHE-140 V-M-LEU-141 V-M-ASN-142 V-S-ASN-142 V-M-GLY-143 V-S-CYS-145 V-S-ASP-153 V-M-MET-165 V-S-MET-165 V-M-GLU-166 V-S-GLU-166 V-M-PHE-181V-S-GLN-189 V-S-TRP-207 V-M-ASP-216 V-S-ASP-216 V-M-ARG-217 V-S-ARG-217 V-M-TRP-218V-S-TRP-218 V-S-ARG-222 V-S-GLU-240 V-M-PRO-241 V-S-ASN-277 V-S-ARG-279 V-M-ALA-285 V-S-LEU-286 V-S-GLU-288 V-S-PHE-291 V-M-PHE-294V-S-PHE-294 V-

S-ARG-298 V-S-GLN-299 V-M-GLY-302 V-M-VAL-303 V-S-VAL-303 V-S-PHE-305 V-M-GLN-306



consensus_SARS coronavirus WH20_-Triptorelin	-111.8
consensus_SARS coronavirus WH20_-Halaven	-107.8
consensus_SARS coronavirus WH20_-Pazobanib	-105.4
consensus_SARS coronavirus WH20_-Votrient	-104.8
consensus_SARS coronavirus WH20_-Aloxi	-100.7
consensus_SARS coronavirus WH20_-Bosulif	-98.6
consensus_SARS coronavirus WH20_-Picato	-95.6
consensus_SARS coronavirus WH20_-Velcade	-94.4
consensus_SARS coronavirus WH20_-Aliqopa	-91.2
consensus_SARS coronavirus WH20_-Xermelo	-90.5
consensus_SARS coronavirus WH20_-Nerlynx	-90.4
consensus_SARS coronavirus WH20_-Zytiga	-90
consensus_SARS coronavirus WH20_-Jevtana	-89.1
consensus_SARS coronavirus WH20_-Zykadia	-89.1
consensus_SARS coronavirus WH20_-Iclusig	-88.7
consensus_SARS coronavirus WH20_-Pomalyst	-88.7
consensus_SARS coronavirus WH20_-Folotyn	-86.3
consensus_SARS coronavirus WH20_-Dabrafenib	-86
consensus_SARS coronavirus WH20_-Cometriq	-85.9
consensus_SARS coronavirus WH20_-Levoleucovorin	-85.8
consensus_SARS coronavirus WH20_-Mekinist	-85.8
consensus_SARS coronavirus WH20_-Varubi	-84.8
consensus_SARS coronavirus WH20_-Imbruvica	-84.1
consensus_SARS coronavirus WH20_-Akynzeo	-84
consensus_SARS coronavirus WH20_-Torisel	-83.2
consensus_SARS coronavirus WH20_-Cotellic	-83.1
consensus_SARS coronavirus WH20_-Stivarga	-83.1
consensus_SARS coronavirus WH20_-Venclexta	-82.8

Table 1. Docking Energy Rankings of the FDA Cancer -Triptorelin-Halaven-Pazobanib-Votrient-Aloxi-Bosulif-Picato-Velcade-Aliqopa-Xermelo-Nerlynx-Zytiga-Jevtana-Zykadia-Iclusig-Pomalyst-Folotyn-Dabrafenib-Cometriq-Mekinist-Varubi-Imbruvica-Akynzeo-Torisel-Cotellic-Stivarga-Venclexta Drugs within the MMPTTLFAGTHITMTTVYHITVSQIQLSLLKVTAFQHQNSKKTTKLVVILRIGTQVLK

TMSLYMAISPKFTTSLSLHKLLQTLVLKMLHSSSLTSLLKTHRMCKYTQSTALQELLI QQWIQFMMSRRRLLACLCKHKKVSTNLCTHSFRKKQVR the NSP5 OF SARS-COV-2 AND PDB ID 6CS2 AND 6LU7, PDB:1XAK derived consensus motif elements.

Merging of the recored cancer drugs into SivirinavirTM compound.

Pharmacophore modeling and QMMM merging is modern efficient approach for determination of pharmacophore model quality which is widely used in drug discovery. First of all, Triptorelin, Halaven, Pazobanib, Votrient, Aloxi, Bosulif, Picato, Velcade, Aliqopa, Xermelo, Nerlynx, Zytiga, Jevtana, Zykadia, Iclusig, Pomalyst, Folotyn, Dabrafenib, Cometriq, Mekinist, Varubi, Imbruvica, Akynzeo, Torisel, Cotellic, Stivarga, Venclexta virtually selected drugs were then recored and fragmentized to structurally similar smaller compounds that belong to the chemical class of imuquimod, Regadenoson, lisdexamfetamine, sumatriptan, emedastine, famotidine, nadolol, antazoline, atenolol, pindolol, ethambutol, midodrine, pirbuterol, nabumetone, minoxidil, diflunisal active compounds found in the SARS-COV-2 AND PDB ID 6CS2 AND 6LU7, PDB:1XAK screening process but possess different activity. To merge the re-cored cancer fragments into similarity indexes, of the number of active compounds in the top of the ratio of combining imuquimod, Regadenoson, lisdexamfetamine, sumatriptan, emedastine, famotidine, nadolol, antazoline, atenolol, pindolol, ethambutol, midodrine, pirbuterol, nabumetone, minoxidil, diflunisal Triptorelin, Halaven, Pazobanib, Votrient, Aloxi, Bosulif, Picato, Velcade, Aliqopa, Xermelo, Nerlynx, Zytiga, Jevtana, Zykadia, Iclusig, Pomalyst, Folotyn, Dabrafenib, Cometriq, Mekinist, Varubi, Imbruvica, Akynzeo, Torisel, Cotellic., Stivarga, Venclexta pharmacophore modeling we summed the [82-96] coefficients obtained for each individual pairwise comparison and divided this number by 1sαi∂H∂p(Qi,Pi) to normalize them as inputs inserted to the T=xi,yi,i=1,2minw,b,ξqk+1=qk+ΔtΣi=1sαi∂H∂p(Qi,Pi)+ΔWΣi=1sβi∂h∂p(Qi,Pi), 12w2+CΣi=1lξis.t. yiw•Φxi+b≥1and resulting to the (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide pharmacophoric types occurring with the highest frequency of nitrogen atoms attached to carbon atoms with 3 [HC33] or 2 [HC32] hydrogens, sp2 aromatic carbon [CA], hydrogen on aromatic carbon [HA], based on the set of active compounds sp3 carbon atoms with 2 [C32] or 3 [C33] hydrogen atom attached to nitrogen atom in a closed

pharmacophore merging system as calculated from the ringξi,i=1,2,…,lξi≥0, i=1,2,…,l, minα 12Σi−1l Σj=1lyiyjKxi,xjαiαj−Σj=1lαjs.t. starting from a structure file in protein data bank [pdb] or mol2 formats comprising all atoms, GAAMP parameterization proceeded in three mains steps: [1] ⟨w,p⟩=Σi=1nwi•pi. based on the values of pharmacophore features weights to determine how many compounds contribute on only three receptor ligand complexes as calculated:

F(x)={1forx>00forx≤0.Y=f[⟨w,p⟩]=f(Σi=1nwi•pi).(u1u2up)=f((v01v02…v0nv11v12…v1pvp 1vp2…vpn)•(1x1xn)).Σi=1lyiαi=0,0≤αi≤C, resulting to the (2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-{[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]formamido}propyl]-4,5-dihydroxy-2-(methylsulfanyl)oxan-3-yl hexadecanoate(2S)-4-methyl-N-[(1S)-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}-2-phenylethyl]-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]-4-phenylbutanamido]pentanamide i=1,2,…,l. b=yj−Σi=1lyiαiKxi,xj. gx=Σi=1lαiyiKxi,xj+b. to identify for ligand binding to the receptor more important features from the complexes Kpolyx,y=xty+1dKrbfx,y=exp−x−y22g2, (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol4-[(1S)-1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl]-2-(hydroxymethyl)phenolmethyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate(1S)-3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate(2S)-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]carbamoyl}-1-methoxy-2-methylethyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethyl-2-[(2S)-3-methyl2(methylamino)butanamido]butanamidepropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoatemethyl N-[(2S)-1-[(2S)-2-({4-[(2S,5S)-1-(4-tert-butylphenyl)5{4[(2S)1[(2S)2[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidine-2-amido]phenyl}pyrrolidin-2-yl]phenyl}carbamoyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate26-(4-nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diolmethyl N-[(2S)-1-[(2S)-2-{4-[(9S)-5-{2-

[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-4-yl}-9-phenyl-8-oxa-10-azatetracyclo[8.7.0.0B²,β•.0B′HB′H,B′Hβ • ¶]

To parameterize (configure) the Quantum repeaters of imperfect local operations in quantum communication module of weight rescoring we have performed a series of docking free energy screenings against selected models, including pharmacophore hypotheses with excluded volumes, which were generated similarly to usual features on hydrogen atoms of amino acid residues in the active site of SARS-COV-2 studied crystal complexes within selected cancer drug ofligands. To simplify the model, heavy atoms were not involved. Additionally, we have used pharmacophore feature weights which were calculated accordingly to formula:(3).The final results of weight rescoring the module for weight rescoring automatically performs pharmacophore screening using BiogenetoligandorolTM, selects compounds conformers with the lowest RMSD values and represents each ligand as a set of pharmacophore features. heptadeca-1(17),2(7),3,5,11,13,15-heptaen-14-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate regarding the internal energy terms, this functional form is essentially the same as that used in the non-polarizable AMBER30and CHARMM4 force fields, e.g., CHARMM includes Urey-Bradley that are absent from AMBER. The most important difference concerns the 1-4 non-bonded charge-charge MIS¨I=FI[S]-MIS˙Ipη1q1ṗη1=ΣIMIS˙I2-NfkBTphys-pη2q2pη1ṗηj=pηj-12qj-1-kBTphys-pηj+1qj+1pηj,j=2,⋯,nc-1,ṗηj=pηj-12qj-1- including the development of mathematical tools: kBTphys,j=nc,η˙j=pηjqj,j=1,⋯,nc. forModule for calculation of pharmacophore feature weights after superposition of averaging of pharmacophore interactions,whichareKmixx,x′=Σpταi=Σμ=0smiμlμ,s(0)=mi0,0=Σμ=0smiμlμ,s(1)=mis,l¯i,s1(τ)=Σμ=0smiμl˙μ,s(τ). mj0 mjμmjsa¯ijb¯ij(αi,ci)i=1r=1UmpKpx,x′, 2-[1-({[(1R)-1-{3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetate(1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0B²,β • ¶]decane-3,5-dione(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamideΣp=1Ump=1,0<mp<0, p=1,…,U, It covers all FDA-approved drugs, compounds in midst of (Mupirocin) a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents as an input for this module unit ‖V~−V‖≤η. After that, clusters of (Ellagic acid acid) and (Katsumadain) merged into larger ones until the final pharmacophore features are collected after each iteration at one

point if they are also closer than a certain threshold distance as calculated from the ‖H≤Δ′−E~(H)‖≤ϵ and resulting to the a-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.0B³,B′HB′H.0β□′,β□′E.0B′Hβ□′,B′Hβ□′H]henicosa-1(13),2,4(8),6,9,11,14,16,18-nonaen-17-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate molecules under(Nefazodone) where w(fi) — pharmacophore feature weight, H≤Δ′=P≤Δ(H′)H′ E~ E~ (Synribo) a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies experimental. The SDF files were downloaded for each N-{6-[(9H-fluoren-9-yl)dimethylazaniumyl]hexyl}-N,N-dimethyl-9H-fluoren-9-aminium4-{[(1R)-2-[(4P)-5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoate(1R)-1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate compound from DrugBank, Then, we have developed the software unit (module) for weight rescoring. During screening with BiogenetoligandorolTM, ligands are represented as a set of pharmacophore features for calculating the coefficient, and then RMSD values between compound pharmacophore features and model are calculated which the ratio between the mean values of the complexes of ligand pharmacophore features of the descriptor with model are analyzed. For each pair of matched ligand pharmacophore which will multiply the active and inactive Iigands features and model was calculated partial score, which is product of default score (each type of feature has its own score) and feature weight. The value of partial score depends from validation set on the degree of partial overlap 2. descr(i) > aver(i) — dev(i) ∧ descr(i) < aver(i)+ dev(i) ⇒ K := K + k(i) * 3 (5);3. descr(i) < aver(i) — dev(i) ∨ descr(i) > aver(i)+ dev(i) ⇒ K := K k(i) (between ligand pharmacophore features and model the more overlap, the higher score. The sum of partial scores forms final score. Therefore, formula for final score calculation is following:(2),where S — the final score, w(fi) — pharmacophore feature weight, Sdef(fi) — default score of pharmacophore features, t — pharmacophore feature radius, d — the distance between matched ligand pharmacophore feature and model whereas the SMILES files were downloaded for (Fulvestrant) a drug for the treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy as an input to the|ZH′(β)− (p+q)ZH(β)|(p+q)ZH(β)≤dm−ne−(Tenofovir) an antiviral acyclic nucleoside phosphonate with potent inhibitory reverse transcriptase viral properties as an input for the βΔ(p+q)e−β‖H‖+(eϵβ−1) compounds without 3D SDF files, for

example Saquinavir, Lopinavir, Ritonavir and Carfilzomlib. Considering the high similarity between SARS-CoV and SARS-CoV-2, we aligned the protein sequence of SARS-CoV to SARS-CoV-2 genome and selected the best match ψE0,0= (Talfuprost) a prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertensionΣE′,E″aE,E′,E″ψE′E″θ(E,E′,E″) m(fi) — the number of compounds of (Pazopanib) which inhibits the cyclin-dependent kinase (CDK), which is usually over-expressed in cancerous cells; into δE·T(n)∈Ω1polydp=(∂H∂qξT∗Qq+∂H∂pξT∗Qp) [(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido] from Superposition of the butyl] boronic acid (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0B²,β • ¶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0B²,β□•.0B′HB²,B′Hβ□¶]hexadeca-1(16),9,12,14-tetraene-4-carboxamidehexadecyl(2-{[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino}ethyl)dimethylazanium(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoatepropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoateN-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-[80,120] methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-aminewhich contribute tothe feature of the dt(∂h∂qξT∗Qq+∂h∂pξT∗Qp)∘dW=(dH•ξT∗Q)dt(dh•ξT∗Q)∘dW=0, (n).H=2-[(3R,11S,17S,20S,25aS)-3-carbamoyl-11-{4[(diaminomethylidene)amino]butyl}-20-[(1H-indol-3-yl)methyl]-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetate Σi=0nσiz. UN, (Carvedilol)yx=x·ymodN0≤x<Nxotherwise HN, (Temsirolimus) with potential antineoplastic activity y=UN,y+UN, y† UN,yt USEEMψE0,0= region as the corresponding bis({[(propan-2-yloxy)carbonyl]oxy}methyl) {[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methanephosphonate(1S,3aS,3bR,4R,9bS,11aS)-11a-methyl-4-{9-[(S)-4,4,5,5,5-pentafluoropentanesulfinyl]nonyl}-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol 1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate (Deferoxamine)ψE ΣE′aE′E′, θ(E′), H= ΣjHj,protein H= Σi, jmAi, jai†aj+12ΣijBi sequence for SARS-CoV-2. Using this jaiaj+12Σi, jBj, i*ai†aj†A=A†, 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-{[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoate1-

[(2R)-butan-2-yl]-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-onepropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoate(2S)-1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol (Halaven), we obtained all the B=B† ai†, ai mn PrE′E-E′≤δE≥η. E(H)=U(H⊕p⊕H¯⊕q)U† H¯ E(H)=V(H⊗P+H¯⊗Q)V† E~(H)=V~(H⊗P+H¯⊗Q)V~† E~(1)=P≤Δ(H′)‖V~−V‖≤η‖H≤Δ′−E~(H)‖≤ϵH≤Δ′=P≤Δ(H′)H′E~E~|ZH′(β)−(p+q)ZH(β)|(p+q)ZH(β)≤dm−ne−βΔ(p+q)e−β‖H‖+(eϵβ−1).Estate(N(ρ))=N′(Estate(ρ))+O(η),H′=H⊗|+y{+H¯⊗|−y} |±y}=(|0{±i|1})/2 ΔtΔE≥12δE·T(n)∈1poly(n) 28-protein {Hn}n=1∞ (Adefovir){Un}n=1∞ {Un}n1T Σt=0T1t[({[2(6amino9Hpurin9yl)ethoxy]methyl}({[(2,2dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoateN'-(5-aminopentyl)-N'-hydroxy-N-[5-(N-hydroxy-[({[2-(6-amino-9Hpurin9yl)ethoxy]methyl}({[(2,2dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoateN'-(5-aminopentyl)-N'-hydroxy-N-[5-(N-hydroxy-3-{[5-(N-vpn)•(1x1xn)).(y1y2yp)=f((w01w02…w0nw11w12…w1pwp1wp2…wpn)•(1x1xn)). D={(xi,yi) | xi∈ℝP,yi∈{−1,1}}The last term in the Lagrangian invokes orthonormality constraintsduring the classical evolution of the Kohn–Sham orbitals [Marx and Hutter, 2009]. For details of this implementation, see Laio et al. [2002]and Sahoo and Nair [2016]. Where having the shell k harmonically bound to the core atom as calculated from the the optimal entanglement swapping quantum repeater nodes Ri∈V, i=1,…,q. Let E={Ej}, j=1,…,m method that swaps an incoming density matrix ρ and maximizes the entanglement rate of the quantum repeaters at the different entanglement swapping sets with an outgoing density matrix σ as function of the noise contains all the N outgoing density matrices of the local memory and local operations that are shared by Rj during a swapping period πS; thus, 𝒮O(Rj)=∪Ni=1σi and |𝒮O(Rj)|=N.: A∈VB∈VRi∈Vi=1,…,qE={Ej}j=1,…,mVEjLll=1,…,rxjyjEjN=(V,S)|V|SLll=1,…,rELl(x,y)xyd(x,y)Ll=2l−1,LlELl(x,y)d(x,y)Ll−1xyRjUSRjRjRjNNRjρiiρiRiσkσkRkUSRjSI(Rj)SO(Rj)RjdABd=2|β00⟩AB|β00⟩=12(|00⟩+|11⟩),σABσF=⟨β00|σ|β00⟩,F≥0.98σF′Fin<F′≤1,FinBF(ELli)LlELlidELliFd=2ELliCc:BF(ELli)≥BF□(ELli),for∀i,BF□(ELli)FELliBF(ELli)ELliBF□(ELLi)jRjρ|β00⟩=12(|00⟩+|11⟩)Rj−1σRj|β00⟩Rj+1USjRjρσRj−1Rj+1CtC=1/fCoCRjfCoCπSSI(Rj)=∪iρiUSSO(Rj)=∪iσiπS=xtCxSI(Rj)SI∗(Rj)SI(Rj)Q=∑i=1N|Bi|πSRjNRj|Bi|iπSSI(Rj)=∪i=

1Qρi|SI(Rj)|=QSO(Rj)SO∗(Rj)SO(Rj)NRjπSSO(Rj)=∪i=1Nσi|SO(Rj)|=NS(Rj)RjS(Rj)=SI(Rj)∪SO(Rj).S(Rj)S∗(Rj)S∗(Rj)=SI∗(Rj)∪SO∗(Rj),|S∗(Rj)|=Q+N.S(Rj)S(Rj)|S(Rj)|<Q+N.S∗(Rj)Sˆ(Rj)=SˆI(Rj)∪SˆO(Rj)πS|Sˆ(Rj)|=N+NπSSRj(πS)((Ri,σk))SI(Rj)RjRiσkSO(Rj)ZRj(πS)((Ri,σk))=|SRj(πS)((Ri,σk))|.|B(Ri(πS),σk)|RiσkπSZRj(πS′)((Ri,σk))ZRj(πS′)((Ri,σk))=ZRj(πS)((Ri,σk))+|B(Ri(πS),σk)|,πS′ρσPr(ρ,σ)=x≥0|BRi(πS)|RjπS|BRj(πS)|=∑i,k|B(Ri(πS),σk)|,|B(Ri(πS),σk)|RiσkπS|BRi(πS)||BRj′(πS)|Rj|BRj′(πS)|=1−LN11+D(πS)(|BRj(πS)|),L0<L≤ND(πS)πSSI(Rj)SO(Rj)RjRjζ(πS)Rjε>0B>0limπS→∞Pr(|SI(πS)(Rj)|>B)<ε,SI(πS)(Rj)RjπS|SI(πS)(Rj)|RjSI(πS)(Rj)ζ(πS)RjlimπS→∞supE(|SI(πS)(Rj)|)<∞.γ0≤γ≤1γ=0πSS∗(Rj)γ>0S(Rj)πSγSI(Rj)SO(Rj)πSSˆ(Rj)|SˆI(Rj)|=N|SˆO(Rj)|=N|Sˆ(Rj)|=N+N=2NZRj(πS)((Ri,σk))SRj(πS)((Ri,σk))i=1,…,Nk=1,…,NZRj(πS)((Ri,σk))=1S∗(Rj)|SI∗(Rj)|=Q>N|SO∗(Rj)|=N|S∗(Rj)|=Q+NSRj(πS)((Ri,σk))i=1,…,Nk=1,…,NZRj(πS)((Ri,σk))≥1S(Rj)SI(Rj)|S∗(Rj)|=Q′+MQ′≤QM=N−LLπSSRj(πS)((Ri,σk))σkπSSO(Rj)|SO(Rj)|=MSRj(πS)((Ri,σk))i=1,…,Nk=1,…,MZRj(πS)((Ri,σk))≥0SI(Rj)SO(Rj)RjSI(Rj)SO(Rj)USω(γ(πS))S(Rj)γ(πS)>0γ(πS)πSS∗(Rj)γ(πS)=0ω(γ(πS)=0)=ω∗(πS)πSS(Rj)ω(γ(πS))≥ω∗(πS)−f(γ(πS))ω(γ(πS))<ω∗(πS)Sˆ(Rj)ωˆ(πS)≤ω∗(πS)πSζik(ρA,σk)ζik(ρA,σk)=1,ifρA∈SRj(πS)((Ri,σk))0,otherwise,ζik(ρA,σk)=1ρASRj(πS)((Ri,σk))σkζ(πS)=ζik(ρA,σk)i≤N,k≤NRjπSZRj(πS)((Ri,σk))ω(πS)ζ(πS)πSω(πS)=∑i,kζik(ρA,σk)ZRj(πS)((Ri,σk))=⟨ζ(πS),ZRj(πS)⟩,⟨·⟩ZRj(πS)πSZRj(πS)=ZRj(πS)((Ri,σk))i≤N,k≤N,ζ(πS)γ(πS)=0ζ∗(πS)ω(γ(πS)=0)=ω∗(πS)ω∗(πS)ω∗(γ(πS)=0)=maxζ∗(πS)⟨ζ∗(πS),ZRj(πS)⟩,ζ∗(πS)γ(πS)=0χ(πS)γ(πS)>0χ(πS)={(χik(ρA,σk))x,x=Mi+k,i=0,…,M−1,k=0,…,M−1}|χ(πS)||χ(πS)|=maxk=0,…,M−1∑x=0M−1(χik(ρA,σk))Mx+k,∑y=0M−1(χik(ρA,σk))Mk+y,|χ(πS)|≤1⟨ζ□(πS),ZRj(πS)⟩−⟨χ(πS),ZRj(πS)⟩≥0L(ZRj(πS))ZRj(πS)L(ZRj(πS))=∑i,k(ZRj(πS)((Ri,σk)))2.E(L(ZRj(πS′))−L(ZRj(πS))|ZRj(πS))≤−ε|ZRj(πS)|,ZRj(πS)ε>0πSγ(πS)=0Rjωˆ(πS)Sˆ(Rj)f(γ(πS))=0ωˆ(πS)≤ω∗(πS).γ(πS)>0ζ(πS)≠ζ∗(πS)ω∗(πS)ω(γ(πS))=maxζ(πS)⟨ζ(πS),ZRj(πS)⟩<ω∗(πS),γ(πS)ω∗(πS)ω(γ(πS))<ω∗(πS)ω(γ(πS))≥ω∗(γ(πS)=0)−f(γ(πS)),f(·)0≤f(γ(πS))<c(γ(πS)),limγ(πS)→∞f(γ(πS))γ(πS)=0,γ(πS)≥γ(πS=0)c>0E(L(ZRj(πs′))−L(ZRj(πS))|ZRj(πS))≤−ε,ε>0■ζ(πS)γ(πS)>0S(Rj)γ(πS)>0πSζ(πS)S(Rj)L(X)M×MXL(X)=∑i,k(xik)2,xik(i,k)XC1C2C1>0C2>0ζ(πS)γ(πS)>0E(ΔL|ZRj(πS))≤−C1ω(γ(πS)=0),ΔLL(ZRj(πS′))L(ZRj(πS))πs′ΔL=L(ZRj(πs′))−L(ZRj(πS)),ω(γ(πS)=0)=ω∗(πS)≥C2,ΔLΔL=∑i,k(ZRj(πs′)((Ri,σk)))2−(ZRj(πS)((Ri,σk)))2=∑i,k(ZRj(πs′)((Ri,σk))−ZRj(πS)((Ri,σk)))(ZRj(πs′)((Ri,σk))+ZRj(πS)((Ri,σk))),ZRj(πs′)ZRj(πs′)=(ZRj(πS)−ζik(ρA,σk))+|B¯(Ri(πs′),σk)|≤max((ZRj(πS)−ζik(ρA,σk))+|B¯(Ri(πs′),σk)|,1),|B¯(Ri(πs′),σk)|≤1Riσkπs′|B¯(Ri(πs′),σk)|=|B(Ri(πs′),σk)||BRj(πS)|,|BRj(πS)|=∑i,k|B(Ri(πS),σk)|RjNΔL≤∑i,k(|B¯(Ri(πs′),σk)|−ζik(ρA,σk))((2ZRj(πS)((Ri,σk))+1)+1)≤∑i,k(|B¯(Ri(πs′),σk)|−ζik(ρA,σk))((2ZRj(πS)((Ri,σk))))+2M2,E(ΔL|ZRj(πS))≤2∑i,kZRj(πS)((Ri,σk))(E(|B¯(Ri(πS),σk)|)−ζik(ρA,σk)|ZRj(π

S))+2M2=2∑i,kZRj(πS)((Ri,σk))(|B¯(Ri(πS),σk)|−ζik(ρA,σk))+2(N−L)2,E(|B¯(Ri(πS),σk)|) RiσkπSω(πS(γ(πS)>0))ζ(πS(γ(πS)>0))γ(πS)>0πSω(πS(γ(πS)>0))=⟨ζ(πS(γ(πS)>0)),ZRj(πS)⟩,α ikαik=ZRj(πS)((Ri,σk))B¯(Ri(πS),σk).∑i,kαik≤∑zvz⟨ζz(πS(γ(πS)>0)),ZRj(πS)⟩=∑zvzωz′(πS(γ(πS)>0)),vz≥0ζz(πS(γ(πS)>0))zγ(πS)>0ωz′(πS(γ(πS)>0))ζz(πS(γ(πS)>0))E(ΔL|ZRj(πS))E(Δ L|ZRj(πS))≤2∑zvzωz′(πS(γ(πS)>0))−ω(πS(γ(πS)>0))+2(N−L)2=2∑zvzωz′(πS(γ(πS)>0))−ω(π S(γ(πS)=0))+ω(πS(γ(πS)=0))−ω(πS(γ(πS)>0))+2(N−L)2≤2∑zvz−1ω(πS(γ(πS)=0))+2f(γ(πS)) +2(N−L)2=−2C1ω(πS(γ(πS)=0))+2f(γ(πS))+2(N−L)2,C1=1−∑zvz.C20<C2≤ω(πS(γ(πS)=0)), E(ΔL|ZRj(πS))≤−C1ω(πS(γ(πS)=0))E(ΔL|ZRj(πS))≤−ε,εε=C1ω(πS(γ(πS)=0)),limπS→∞Pr(|S I(πS)(Rj)|>B)<C1ω(πS(γ(πS)=0)),■ζ(πS)γ(πS)>0πSζ□(πS)γ(πS)=0S□(Rj)Sˆ(Rj)ω□(γ(πS)=0)ζ□(πS)γ(πS)=0S□(Rj)ζ□(πS)ζ□(πS)=argmaxζs(πS)∈L(ζ(πS))⟨ζ□(πS),ZRj(πS)⟩,S(ζ(πS))N! πSN|SO(Rj)|=NSˆ(Rj)S(ζ(πS))N!|SI(Rj)|=|SO(Rj)|=NΔLL(ZRj(πS))L(ZRj(πS′))L(ZRj(πS))= ∑i,k(ZRj(πS)((Ri,σk)))2L(ZRj(πS′))=∑i,k(ZRj(πS′)((Ri,σk)))2,πS′ΔL=L(ZRj(πS′))−L(ZRj(π S)).S□(Rj)E(ΔL|ZRj(πS))ζ□(πS)E(ΔL|ZRj(πS))≤−2C1ω□(γ(πS))+2N2,C1E(ΔL|ZRj□(πS))≤ −ε|ZRj□(πS)|,ε|ZRj□(πS)|S□(Rj)πS|ZRj□(πS)|=∑i,kZRj(πS)((Ri,σk))=|SI(πS)(Rj)|.E(ΔL|ZRj □(πS))≤−ε| and resulting to the: IP.i=1n.547.3592131NC(CN1CCCC(C2=CCOCC(NN3CCCN([NH3+])C3O)NCCO2)CCN C1)N=P1(O)CC1N530.332664NC(CN1CCCC(C2CCOCC(=[NH+]N3CCCN=C3O)N=CCO 2)CCNC1)NP1(O)CC1N116.0818384[NH3+]N1CCCNC1=O383.2765154OC1=NCCCN1[NH+]=C1COCCC(C2CCCNCNCC2)OCCN1513.3061149NC(CN1CCCC(C2=CCOCC(=[N H+]N3CCCN=C3O)N=CCO2)CCNC1)NP1(O)CC1529.3486484NC(CN1CCCC(C2=CCOC C(=NN3CCCN([NH3+])C3)N=CCO2)CCNC1)NP1(O)CC1N115.0978228NN1C=CCN([N H3+])C1382.2924998[NH3+]N1CCCN(N=C2COCCC(C3CCCNCNCC3)OCC=N2)C1512.3 220993NC(CN1CCC=C(C2=CCOCC(=NN3CCCN([NH3+])C3)N=CCO2)CCNC1)NP1(O) CC1432.2846512NC(CN1CCCC(C2CCOCC(=[NH2+])N=CCO2)CCNC1)NP1(O)CC1N(1 R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19Z,21Z,23Z,25Z,27Z,29Z,31Z,33R,35S,36R,37S)- 33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}- 1,3,5,6,9,11,17,37octahydroxy15,16,18trimethyl13oxo14,39dioxabicyclo[33.3.1]nonatriacont a19,21,23,25,27,29,31heptaeneH′=H⊗|+y}+H¯⊗|−y}carboxylateαTKmixx,x′α=αTΣp=1Um pKpx,x′α=αTm1K1x,x′+m2K2x,x′+⋯+mUKUx,x′α=m1αTK1x,x′α+m2αTK2x,x′α+⋯+mUα TKUx,x′α≥0.Vidk+1=ωVidk+c1r1Pidk−Xidk+c2r2Pgdk−Xidk,Xidk+1=Xidk+Vidk+1,which willmultiplytheweightscore,descr(i)ACC=TP+TNTP+TN+FP+FN,SEN=TPTP+FN.ωk=ωstar tωstart−ωendTmax−kTmax,T∗Q=Q×Q∗≅RN×RNωk=ωend+ωstart−ωendTmax−kTmax for pharmacophore SARS-COv-2 models generation (2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-

[(2S)-2-[(2S)-5-{[amino(iminiumyl)methyl]amino}-2-[2-(methylamino)acetamido]pentanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]formamido}propanoatethe mean — adjustmentcoefficientofdescriptor,valueofdescriptorωk=ωstart−ωstart−B[q(•),p(•)]=p(tb)q(tb) which was taken from the table of parameters,k(i) ∫tatb[p∘d-H(q(t),p(t))dth(q(t),p(t))∘dW(t)], ωendkTmax2 ωk=ωstart−ωstart−ωend2kTmax− kTmax2 (2-{[(2R)-2,3-bis(hexadecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium(9S)-3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl4oxo4H,6H,7H,8H,9Hpyrido[1,2a]pyrimidin9ylhexadecanoateωk=ωendωstartωend1/1+ck/Tmax.Fgy=Vbestt:maxgen−VAveraget:maxgen2=Vbestt−VAvet2+Vbestt+1−VAvet+12+⋯+Vbestmaxgen−VAvemaxgen2maxgen−t+1, thermostat variables, nc, is chosen to be more than one. [10-122] Here, FI and f[r]k ⟨w,p⟩=Σi=1nwi•pi. F(x)={1for x>00for x≤0. Y=f[⟨w,p⟩]=f(Σi=1nwi•pi) of module for pharmacophore set of feature models averaging, we have obtained quality performing parameterization initial pharmacophore model, for further investigations for optimization of quality parameters of pharmacophore feature radii, weights and default scores by checking the whole set of models which comprised two aromatic features, one hydrophobic feature, two hydrogen bond acceptors and one hydrogen bonddonor.(1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19Z,21Z,25Z,27Z,29Z,31Z,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1] (u1u2up)=f((v01v02…v0nv11v12…v1pvp1vp2…vpn)•(1x1xn)) (y1y2yp)=f((w01w02…w0nw11w12…w1pwp1wp2…wpn)•(1x1xn)). D={(xi,yi) | xi∈ℝP,yi∈{−1,1}}i=1n. are the Cartesian forces on an atom [or nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylate2-methyl-3-[(2E,6E,10E,14E)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaen-1-yl]-1,4-dihydronaphthalene-1,4-dionecore] I and on a shell k connected to core I, respectively. [30-157] as an inputtotheαTKmixx,x′α=αTΣp=1UmpKpx,x′α=αTm1K1x,x′+m2K2x,x′+⋯+mUKUx,x′α=m1αTK1x,x′α+m2αTK2x,x′α+⋯+mUαTKUx,x′α≥0.Vidk+1=ωVidk+c1r1Pidk−Xidk+c2r2Pgdk−Xidk,Xidk+1=Xidk+Vidk+1, ACC=TP+TNTP+TN+FP+FN, SEN=TPTP+FN. ωk=ωstartωstart− ωendTmax−kTmax, resulting to the clustering of oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate5-{[(2S)-2-amino-3-(4-carbamoyl-2,6-

dimethylphenyl)-N-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]propanamido]methyl}-2-methoxybenzoate[(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine{4-[(1S)-2-amino-1-[(isoquinolin-6-yl)carbamoyl]ethyl]phenyl}methyl 2,4-dimethylbenzoatemethyl N-[(2S)-1-[(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino] vector aromatic features. After that from quantum multiplexing over arbitrarily long distances to high-performance quantum networking using a bounded-size quantum reference frame of pheromone update in swarm intelligentMANETsofωk=ωend+ωstart−ωendTmax−kTmaxωk=ωstart−ωstart−ωendkTmax2ωk=ωstart−ωstart−ωend2kTmax−kTmax2ωk=ωendωstartωend1/1+ck/Tmax.Fgy=Vbestt:maxgen−VAveraget:maxgen2=Vbestt−VAvet2+Vbestt+1−VAvet+12+⋯+Vbestmaxgen−VAvemaxgen2maxgen−t+1, [95, 165] solved to a zero-to-one scale between other nystatin pharmacophore features that corresponds to a normalized sum of the individual druggable (1S,5R,13R,14S,17S)-14-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0ƀH,ƀHB³.0β□μ,ƀHβ□•.0β□•,ƀHβ□Ɛ]octadeca-7(18),8,10-triene-10,17-diol(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(2H-1,2,3,4-tetrazol-5-yl) scaffold that between the 0∫≤∫S∫≤∫1 [with 0 corresponding to no overlap between any of the three docking sets, and 1 corresponding to three fully overlapping merging sets based on a Multistage entanglement swapping for the development of the SivirinavirTM multi-targeted pharmacophore model for SARS-COV-2 inhibitors as merged under 2π rotations when solving the S[X,Y]=0X∩Y0min[00X00,00Y00]1T=xi,yi,i=1,2,…,l, minw,b,ξ 12w2+CΣi=1lξis.t. yiw•Φxi+b≥1− ξi,i=1,2,…,lξi≥0, i=1,2,…,l, minα 12Σi−1l E(H)=U(H⊕p⊕H¯⊕q)U†Σj=1lyiyjKxi,xjαiαj−Σj=1lαjs.t. Σi=1lyiαi=0,0≤αi≤C, i=1,2,…,l. b=yj−Σi=1lyiαiKxi,xj. gx=Σi=1lαiyiKxi,xj+b. Kpolyx,y=xty+1dKrbfx,y=exp−x−y22g2, Kmixx. And resulting to the (1S,5R,13R,14S,17S)-14-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy)-4-(prop-2-en1yl)12oxa4azapentacyclo[9.6.1.0ƀH,ƀHB³.0β□μ,ƀHβ□•.0β□•,ƀHβ□Ɛ]octadeca-7(18),8,10-triene-10,17-diol(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate5-{[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]propanamido]methyl}-2-methoxybenzoate[(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine{4-[(1S)-2-amino-1-

[(isoquinolin-6-yl)carbamoyl]ethyl]phenyl}methyl 2,4-dimethylbenzoatemethyl N-[(2S)-1-[(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-1H-1,3-benzodiazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dionepropan-2-yl (2S)-2-{[(R)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro3hydroxy4methyloxolan2yl]methoxy}(phenoxy)phosphoryl]amino}propanoate1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide5-[(1R)-2-(tertbutylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate(2R)-2-(2-amino-2-methylpropanamido)-3-(1H-indol-3-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-formamidoethyl]propanamidemethyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1(6),2,4-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one1-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one.

BiogenetoligandorolTM(COVID2019)

1) INITIALIZE PROCEDURE FOR |BRi(πS)| be the incoming entanglement rate of Rj per a given πS, defined as |BRj(πS)|=∑i,k|B(Ri(πS),σk)|,

2) Forj=1□nS(ζ(πS))N!πSN|SO(Rj)|=NSˆ(Rj)S(ζ(πS))N!|SI(Rj)|=|SO(Rj)|=NΔLL(ZRj(πS)) L(ZRj(πS′))L(ZRj(πS))=∑i,k(ZRj(πS)((Ri,σk)))2L(ZRj(πS′))=∑i,k(ZRj(πS′)((Ri,σk)))2,πS′Δ L=L(ZRj(πS′))−L(ZRj(πS)).S□(Rj)E(ΔL|ZRj(πS))ζ□(πS)E(ΔL|ZRj(πS))≤−2C1ω□(γ(πS))+2 N2,C1E(ΔL|ZRj□(πS))≤−ε|ZRj□(πS)|,ε|ZRj□(πS)|S□(Rj)πS|ZRj□(πS)|=∑i,kZRj(πS)((Ri,σk))=|SI(πS)(Rj)|.E(ΔL|ZRj□(πS))≤−ε|

3) If s j=∗ a p ply 122m1−ℏ2

4) θijk(t+1)=c1r1θPijk(t)+c2r2θGij(t)(c1r1+c2r2)±w·ln[1/uijk(t)]||||1L∑k=1Lθ Pijk(t)−θijk(t)||||,

5) Forj=1□nω(πS(γ(πS)>0))+2(N−L)2≤2∑zvz−1ω(πS(γ(πS)=0))+2f(γ(πS))+2(N−L)2=−2C1ω(πS(γ(πS)=0))+2f(γ(πS))+2(N−L)2,C1=1−∑zvz.C20<C2≤ω(πS(γ(πS)=0)),E(ΔL|ZRj(πS))≤−C1ω(πS(γ(πS)=0))E(ΔL|ZRj(πS))≤−ε,εε=C1ω(πS(γ(πS)=0)),limπS→∞Pr(|SI(πS)(Rj)|>B)<C1ω(πS(γ(πS)=0)),■ζ(πS)γ(πS)>0πSζ□(πS)γ(πS)=0S□(Rj)Sˆ(Rj)ω□(γ(πS)=0)ζ□(πS)γ(πS)=0S□(Rj)ζ□(πS)ζ□(πS)=argmaxζs(πS)∈L(ζ(πS))⟨ζ□(πS),ZRj(πS)⟩,H3+H3+H3+E^p3dim(θ→)CU^Fobj(θ→)=E+TSA^(θ→)(E^p0=I^)E^piFobj(θ→)=S(high-Tlimit)P=Tr[ρC2]Fobj(P,E)=E−TP=E−TTr[ρC2]θ→A^(θ→)|Ψ⟩T=A^(θ→)|Φ⟩θ→gA^g=A^(θ→g)E^piA^(θ→g)E^piθ→eiA^ei=E^piA^(θ→ei){A^ei}H^∈ℂ2n×2n|ψT(k)⟩=∑iαi(k)|λi⟩{Ξ(k):={θ→j}}maxφ→∈Ξ(k)‖φ→−Eθ→∈Ξ(k)(θ→)‖max≤xmaxO(NiterNdim(θ→)(‖H^‖2mink∑i|αi(k)|4+T2)[Γδ]2+1ϵ){ϵμ2(k)}{ϵΣ4(k)}Γ:=maxk(xmax(k)/ϵμ(k),xmax2(k)/ϵΣ2(k))E^piH^=H^0+V^H^0=∑iϵia^i†A^iV^a^i†A^jE^p=exp[π/2(a^i†A^j−a^j†A^i)](|20⟩+|02⟩)/2(|1010⟩+|0101⟩)/212(|0⟩C⊗I^|Ψ⟩T⊗|0⟩P+|1⟩C⊗U^|Ψ⟩T⊗|1⟩P)12(|0⟩C⊗I^|Ψ⟩T+|1⟩C⊗U^|Ψ⟩T)A^=eiφaeiφbσ^z/2eiφcσ^y/2U^=eiφcσ^z/2eiφdσ^y/2eiφeσ^z/2H^=(α−ℓ)I^+βσ^xE^p=eiπσ^z/2U^2kH3+E^piH3+(H2,H3+,H3,H4)E^piH^∈ℂ2n×2nO(Niterκ2pΛ2dim(θ→)(‖H^‖2mink∑i|αi(k)|4+T2)[dim(θ→)δ]2p+4(p+1)+1ϵ)H^=H^0+V^H^0=∑ijhijbi†bjV^H^0=F^V^H^0=∑iϵiai†aiai†ajV^{ai†aj|Ψ⟩}E^ij(θ)=exp[θ(ai†aj−aj†ai)]Dij=⟨Ψ|ai†aj|Ψ⟩ci†cjH^0=F^e−iH^t≈e−iP^1te−iP^2t⋯P^1,P^2,…H^H^=(αββα)H^qubit=αI^+βσ^xI^σ^xH^′=H^−ℓI^H3+U^(t→)=exp[i(∑ijtij(ai†aj)+∑ijkltijkl(ai†aj†akal))]ai†U(t→)U^(t→)=exp[∑ijtij(ai†aj−aj†ai)+∑ijkltijkl(ai†ajak†al−al†akaj†ai)]A^(θ→)A^(θ→)=exp[(∑iθiA^i)t]Eij= exp[π2(ai†aj−aj†ai)]H3+H3+H3+E^p3dim(θ→) If s j=∗

6) Forj=1□nω(πS(γ(πS)>0))+2(N−L)2≤2∑zvz−1ω(πS(γ(πS)=0))+2f(γ(πS))+2(N−L)2=−2C1ω(πS(γ(πS)=0))+2f(γ(πS))+2(N−L)2,C1=1−∑zvz.C20<C2≤ω
SOLVE222m2+V[x1,x2]]Ψ[x1,x2],

7) IForj=(|B¯(Ri(πs′),σk)|−ζik(ρA,σk))((2ZRj(πS)((Ri,σk))))+2M2,E(ΔL|ZRj(πS))≤2∑i,kZRj(πS)((Ri,σk))(E(|B¯(Ri(πS),σk)|)−ζik(ρA,σk)|ZRj(πS))+2M2=2∑i,kZRj(πS)((Ri,σk))(|B¯(Ri(πS),σk)|−ζik(ρA,σk))+2(N−L)2,E(|B¯(Ri(πS),σk)|)Riσkπsω(πS(γ(πS)>0))ζ(πS(γ(πS)>0))γ(πS)>0πSω(πS(γ(πS)>0))=⟨ζ(πS(γ(πS)>0)),ZRj(πS)⟩,αikαik=ZRj(πS)((Ri,σk))B¯(Ri(πS),σk).∑i,kαik≤∑zvz⟨ζz(πS(γ(πS)>0)),ZRj(πS)⟩=∑zvzωz′(πS(γ(πS)>0)), 1□n If s j=∗ For theSOLVEiℏ∂ψ1n[x1,t]∂t=−ℏ22m1∂2ψ

8) ||Aj⟩=||x1j⟩⊗||x2j⟩⋯⊗||xmj⟩=[cosθ1jsinθ1j]⊗[cosθ2jsinθ2j]⋯⊗[cosθmjsinθmj]=⎡⎣⎢⎢⎢⎢⎢cosθ1j×cosθ2j×⋯×cosθmjcosθ1j×cosθ2j×⋯×sinθmj⋯sinθ1j×sinθ2j×⋯×sinθmj⎤⎦⎥⎥⎥⎥⎥=⎡⎣⎢⎢⎢⎢⎢Aj1Aj2⋯Ajm⎤⎦⎥⎥⎥⎥⎥

9) I For j=1□n If s j=∗ For theSOLVE1n[x1,t]∂x12+∂n∂x2n[V[x1,x2]Ψ[x1,x2]]

10) ||Aj⟩=||x1j⟩⊗||x2j⟩⋯⊗||xmj⟩=[cosθ1jsinθ1j]⊗[cosθ2jsinθ2j]⋯⊗[cosθmjsinθmj]=⎡⎣⎢⎢⎢⎢⎢cosθ1j×cosθ2j×⋯×cosθmjcosθ1j×cosθ2j×⋯×sinθmj⋯sinθ1j×sinθ2j×⋯×sinθmj⎤⎦⎥⎥⎥⎥⎥=⎡⎣⎢⎢⎢⎢⎢Aj1Aj2⋯Ajm⎤⎦⎥⎥⎥⎥⎥

i) id(t+1)=vid(t)+c1×Y1()×pibd(t)−xid(t)+c2×Y2()×pgd(t)−xid(t)xid(t+1)=xid(t)+vid(t+1),1≤i≤n,1≤d≤Dvid(t+1)=wt×vid(t)+c1×Y1()×pibd(t)−xid(t)+c2×Y2()×pgd(t)−xid(t)w(t)=wini−wini−wendTmax×tHwo=THwh1,...,whNH,b1,...,bNH,XX1,...,XXN=gwh1·XX1+b1⋯gwhNH·XX1+bNH⋮⋱⋮gwh1·XXN+b1⋯gwhNH·XXN+bNHwo=wo1T⋮woNHTandT=t1T⋮tNT.wo=H+Td(g)=∑j=1c∑k=1,k=jc12|μgj−μgk|σgj+σgk+12lnσgj2+σgk22σgjσgkμgjμgkσgjσgkpg(i+1)=Xj,f(Xj)−f(pg(i))≥εXjwith theP=e−|f(Xj)−f(pg(i))|T(i+1),|f(Xj)−f(pg(i))|<εT(i+1)=T0−T0−TendItmax×(i+1)CCSC−IPSO−ELM=O(NTG×NTrain)+O(l×Ng1)+O(lse×Ng2)+O(NPSO×IterPSO)

11) IForj=1□nIf s j=∗ SOLVE|x2=X2[t]−ℏ22m2ψ1n+2[x1,t]+iℏdX2[t]dtψ1n+1[x1,t].

12) Forj=1□n(πS)−ζik(ρA,σk))+|B¯(Ri(πs′),σk)|,1),|B¯(Ri(πs′),σk)|≤1Riσkπs′|B¯(Ri(πs′),σk)|=|B(Ri(πs′),σk)||BRj(πS)|,|BRj(πS)|=∑i,k|B(Ri(πS),σk)|RjNΔL≤∑i,k(|B¯(Ri(πs′),σk)|−ζik(ρA,σk))((2ZRj(πS)((Ri,σk))+1)+1)≤∑i,k(|B¯(Ri(πs′),σk)|−ζik(ρA,σk))((2ZRj(πS)((Ri,σk))))+2M2,E(ΔL|ZRj(πS))≤2∑i,kZRj(πS)((Ri,σk))(E(|B¯(Ri(πS),σk)|)−ζik(ρA,σk)|ZRj(πS))+2M2=2∑i,kZRj(πS)((Ri,σk))(|B¯(Ri(πS),σk)|−ζik(ρA,σk))+2(N−L)2,E(|B¯(Ri(πS),σk)|)Riσkπsω(πS(γ(πS)>0))ζ(πS(γ(πS)>0))γ(πS)>0πSω(πS(γ(πS)>0))=⟨ζ(πS(γ(πS)>0)),ZRj(πS)⟩,αikαik=ZRj(πS)((Ri,σk))B¯(Ri(πS),σk).∑i,kαik≤∑zvz⟨ζz(πS(γ(πS)>0)),ZRj(πS)⟩=∑zvzωz′(πS(γ(πS)>0))Ifsj=∗ SOLVE∂n∂x2n[V[x1,x2]Ψ[x1,x2]]|x2=X2[t]=Σk=0n [nk]ψ1n−k[x1,t]∂kV[x1,x2]∂x

13) IFor∑i,k(ZRj(πS)((Ri,σk)))2.E(L(ZRj(πS′))−L(ZRj(πS))|ZRj(πS))≤−ε|ZRj(πS)|,ZRj(πS)ε>0πSγ(πS)=0Rjω^(πS)S^(Rj)f(γ(πS))=0ω^(πS)≤ω∗(πS).γ(πS)>0ζ(πS)≠ζ∗(πS)ω∗(πS)ω(γ(πS))=maxζ(πS)⟨ζ(πS),ZRj(πS)⟩<ω∗(πS),γ(πS)ω∗(πS)ω(γ(πS))<ω∗(πS)ω(γ(πS))≥ω∗(γ(πS)=0)−f(γ(πS)),f(·)0≤f(γ(πS))<c(γ(πS)),limγ(πS)→∞f(γ(πS))γ(πS)=0,γ(πS)≥γ(πS=0)c>0E(L(ZRj(πs′))−L(ZRj(πS))|ZRj(πS))≤−ε,ε>0■ζ(πS)γ(πS)>0S(Rj)γ(πS)>0πS j=1□n If s j=∗ I For j=1□n If s j=∗ SOLVE2k|x2=X2[t] ψin

14) I For j=1□n If s j=∗ SOLVEV[x1,x2]=12kx12+12kx22 w(f) = ∑i = 1Kwi(f)t = c1-c2σ12n+σ22mS(f)=∑k=1KPk(ck−c)2σ2(f)∑k=1KPk(1−Pk)s(g) = ∑i∈N0∑j∈N1I((xj(g)-xi(g)))≤0(xj(g)-xi(g))≤0xi(g)vidnew = w.vidold+c1.rand1(…)×(pbestidold-xidold)+c2.rand2(…)×(gbestidold-xidold)xidnew = xidold+vidnewxidnew = w1.xidold+w2.pbestidold+w3.gbestidoldxidold, pbestidoldgbestidold

15) I For j=1□n If s j=∗ SOLVEV[x w(f) = ∑i = 1Kwi(f)t = c1-c2σ12n+σ22mS(f)=∑k=1KPk(ck−c)2σ2(f)∑k=1KPk(1−Pk)s(g) = ∑i∈N0∑j∈N1I((xj(g)-xi(g)))≤0(xj(g)-xi(g))≤0xi(g)vidnew = w.vidold+c1.rand1(…)×(pbestidold-xidold)+c2.rand2(…)×(gbestidold-xidold)xidnew = xidold+vidnewxidnew = w1.xidold+w2.pbestidold+w3.gbestidoldxidold, pbestidoldgbestidold 1,x2]=12k1x12+12k2x22+12k3[x1−x2]2 [ψ1n,ψ2n] [ψin] ψi0 iℏ

16) IForj=1vid(t+1)=vid(t)+c1×Y1()×pibd(t)−xid(t)+c2×Y2()×pgd(t)−xid(t)xid(t+1)=xid(t)+vid(t+1),1≤i≤n,1≤d≤Dvid(t+1)=wt×vid(t)+c1×Y1()×pibd(t)−xid(t)+c2×Y2()×pgd(t)−xid(t)w(t)=wini−wini−wendTmax×tHwo=THwh1,...,whNH,b1,...,bNH,XX1,...,XXN=gwh1·XX1+b1⋯gwhNH·XX1+bNH⋮⋱⋮gwh1·XXN+b1⋯gwhNH·XXN+bNHwo=wo1T⋮woNHTandT=t1T⋮tNT.wo=H+Td(g)=∑j=1c∑k=1,k=jc12|μgj−μgk|σgj+σgk+12lnσgj2+σgk22σgjσgkμgjμgkσgjσgkpg(i+1)=Xj,f(Xj)−f(pg(i))≥εXjwiththeP=e−|f(Xj)−f(pg(i))|T(i+1),|f(Xj)−f(pg(i))|<εT(i+1)=T0−T0−TendItmax×(i+1)CCSC−IPSO−ELM=O(NTG×NTrain)+O(l×Ng1)+O(lse×Ng2)+O(NPSO×IterPSO)□n If s j=∗ SOLVEΣia˙i[t]φi[x]=−ℏ22m

i) I For j=1□n If s j=∗ oSOLVERPi=[P[A1O1|[θi|CI]]P[A2O1|[θi|CI]]P[A1O2|[θi|CI]]P[A2O2|[θi|CI]]⋯⋯P[AkO1|[θi|CI]]P[AkO2|[θi|CI]]⋮ ⋮⋱⋮P[A1Ov|[θi|CI]] P[A2Ov|[θi|CI]]⋯P[AkOv|[θi|CI]]] [XMT=Σj=1K[rj×[XRPj|CI]]Σj=1KrjYMT=Σj=1K[rj×[YRPj|CI]]Σj=1Krj Stepp=[1,δΔtpv=12δΔtp,ap≥δap&Δtp≥δΔtp&Δtpv≥δΔtpv&Δap≥00,δΔtpv=12δΔtp,ap<δap||Δtp<δΔtp||Δtpv<δΔtpv||Δap<0 valley=[1,δΔtvp=12δΔtv,av≥δav&Δtv≥δΔtv&Δtvp≥δΔtvp0,δvp=12δΔtv,av<δav||Δtv<δΔtv||Δtvp<δΔtvp valley=[1,δΔtvp=12δΔtv,av≥δav&Δtv≥δΔtv&Δtvp≥δΔtvp&Δav≥00,δΔtvp=12δΔtv,av<δav||Δtv<δΔtv||Δtvp<δΔtvp||Δav<0 Lk=K×accmax−accmin4 [θk=αθk−1+βθm,k+γθg,k, θΔ,c≤θc,θΔ,m≤θmθk=βθm,k+γθg,k, θΔ,c≤θc,θΔ,m>θmθk=αθk−1, θΔ,c>θc,θΔ,m≤θmθk=αθk−1+γθg,k, θΔ,c>θc,θΔ,m>θm

θΔ,c=|θm,k I=[1001] X=[0110] Y=[0i−i0] Z=[100−1] H=1/21/2[111−1] S=[100i] |0⟩=[10] |1⟩=[01] [1001] |ψ⟩=1/N1/2Σx=0N−1|x⟩ |x⟩ [|0⟩−|1⟩]/21/2→O−1θ[x]|x⟩[|0⟩−|1⟩]/21/2, ∂[Ca2+]/∂t=D[∂2[Ca2+]/∂2x]+[σ/d2τ] Σδ[x−xi]H[t−ti]H[ti+τ−t], |ψ⟩=1/Dmax1/2Σnj = 0DCmax−1|x⟩ |x⟩[|0⟩−|1⟩]/21/2→OIP3R−1θ[x]|x⟩[|0⟩−|1⟩]/21/2, pO=[[[Ca2+][IP3]KCaI]/[[Ca2+][IP3]+[IP3]KCaI +KIP-31KCaI+[Ca2+]KIP32][[Ca2+]+KCaA]]3, |x⟩=1/41/2ΣMn = 04−1|100⟩ |x⟩=1/41/2ΣMn=04−1|100⟩⟨H⟩=⟨ϕ|H|ϕ⟩⟨ϕ|ϕ⟩=Σx,x′⟨ϕ|x⟩ ⟨x|H|x′⟩⟨x′|ϕ⟩Σx⟨ϕ|x⟩⟨x|ϕ⟩=Σx,x′ϕ[x]¯⟨x|H|x′⟩ϕ[x′]Σx|ϕ[x]|2 ϕ[x]¯ σ1z,σ2z..σnz σiz σiz σiz=1,|σiz⟩ σiz=-1,|σiz⟩ |x⟩=σ1zσ2z..σnz ϕ[x]=P[x] x=[σ1z,σ2z..σnz] P[x]=Σ[h]eΣiaiσiz+Σjbjhj+Σi,jwijσizhjΣx′Σ[h]eΣiaiσiz′+Σjbjhj+Σi,jwijσiz′hj. σiz σiz σzi s[x]=sσ1z,σ2z.. σnz=tanhΣidiσiz+c σiz ⟨H⟩=Σx,x′ϕ[x]¯s[x]¯⟨x|H|x′⟩ϕ[x′]s[x′]Σx|ϕ[x]s[x]|2 Ĥ= Σi,jhijai†aj+12Σi,j,k,lhijklai†aj†akal. aj† σαi∈σx,σy,σz,I H= Σi,αhαiσαi+Σi,j,α,βhαβijσαiσβj+Σi,j,k,α,β,γhαβγijkσαiσβjσγk+.. P[y]=eΣiaiσiz+Σjbjhj+Σi,jwijσizhjΣy′eΣiaiσiz′+Σjbjhj′+Σi,jwijσiz′hj′, Q[y]=e1kΣiaiσiz+Σjbjhj+Σi,jwijσizhjΣy′e1kΣiaiσiz′+Σjbjhj′+Σi,jwijσiz′hj′, θi=2arcsineaiℵkeaiℵk+e-aiℵk γj=2arcsinebjℵkebjℵk+e-bjℵk ⊗iRy[θi]|0i⟩⊗jRy[γj]|0j⟩|0⟩= ΣyO[y]|y⟩|0⟩ O[y]=eΣiaiσizℵk+Σjbjhjℵk Σy′eΣiaiσiz′ℵk+Σjbjhj′ℵk |y⟩=|σ1z..σnzh1..hm⟩-ewijσizhj σizhj θij,1=2arcsinewijℵkewijℵk θij,2=2arcsine-wijℵke|wijℵk ewijσizhj e-1kΣi,j2|wij| Eloc[x]=⟨x|H|ϕ⟩ϕ[x]s[x] Dpk[x]=∂pk[ϕ[x]s[x]]ϕ[x] s[x]

17) I For j=1□n If s j=∗ SOLVEΣiai[t]∂2φi[x]∂x2+V[x,Y]SOLVEΣiai[t]φi[x]−ħ22m

18) I For j=1□n If s j=∗ SOLVEΣici[t]φi[x]+iħdYdt Ai1…id=∑α1=1,…,αd−1=1r1,…,rdG1i1α1G2 H3+H3+H3+E^p3dim(θ→)CU^Fobj(θ→)=E+TSA^(θ→)(E^p0=I^)E^piFobj(θ→)=S(high-T limit)P=Tr[ρC2]Fobj(P,E)=E−TP=E−TTr[ρC2]θ→A^(θ→)|Ψ⟩T=A^(θ→)|Φ⟩θ→gA^g=A^(θ→g)E^piA^(θ→g)E^piθ→eiA^ei=E^piA^(θ→ei){A^ei}H^∈ℂ2n×2n|ψT(k)⟩=∑iαi(k)|λi⟩{Ξ(k):={θ→j}}maxφ→∈Ξ(k)‖φ→−Eθ→∈Ξ(k)(θ→)‖max≤xmaxO(NiterNdim(θ→)(‖H^‖2minkΣi|αi(k)|4+T2)[Γδ]2+1ϵ){ϵμ2(k)}{ϵΣ4(k)}Γ:=maxk(xmax(k)/ϵμ(k),xmax2(k)/ϵΣ2(k))E^piH^=H^0+V^H^0=∑iϵia^i†A^iV^a^i†A^jE^p=exp[π/2(a^i†A^j−a^j†A^i)](|20⟩+|02⟩)/2(|1010⟩+|0101⟩)/212(|0⟩C⊗I^|Ψ⟩T⊗|0⟩P+|1⟩C⊗U^|Ψ⟩T⊗|1⟩P)12(|0⟩C⊗I^|Ψ⟩T+|1⟩C⊗U^|Ψ⟩T)A^=eiφaeiφbσ^z/2eiφcσ^y/2U^=eiφcσ^z/2eiφdσ^y/2eiφeσ^z/2H^=(α−ℓ)I^+βσ^xE^p=eiπσ^z/2U^2kH3+E^piH3+(H2,H3+,H3,H4)E^piH^∈ℂ2n×2nO(Niterκ2pΛ2dim(θ→)(‖H^‖2minkΣi|αi(k)|4+T2)[dim(θ→)δ]2p+4(p+1)+1ϵ)H^=H^0+V^H^0=∑ijhijbi†bjV^H^0=F^V^H^0=∑iϵiai†aiai†

ajV^{ai†aj|Ψ⟩}E^ij(θ)=exp[θ(ai†aj−aj†ai)]Dij=⟨Ψ|ai†aj|Ψ⟩ci†cjH^0=F^e−iH^t≈e−iP^1te−iP^2t⋯P^1,P^2,…H^H^=(αββα)H^qubit=αI^+βσ^xI^σ^xH^′=H^−ℓI^H3+U^(t→)=exp[i(∑ijtij(ai†aj)+∑ijkltijkl(ai†aj†akal))]ai†U(t→)U^(t→)=exp[∑ijtij(ai†aj−aj†ai)+∑ijkltijkl(ai†ajak†al−al†akaj†ai)]A^(θ→)A^(θ→)=exp[(∑iθiA^i)t]Eij=exp[π2(ai†aj−aj†ai)]H3+H3+H3+E^p3dim(θ→) α1i2α2…Gd−1αd−2id−1αd−1Gdαd−1id

19) IForj=1□nIfsj=∗SAi1…id=∑α1=1,…,αd−1=1r1,…,rdG1i1α1G2α1i2α2…Gd−1αd−2id−1αd−1Gdαd−1idOLVEΣibi[t]φi[x].[a˙i]i∂ψ[x,t]∂t=Hψ[x,t]+W[x,t],H3+H3+H3+E^p3dim(θ→)CU^Fobj(θ→)=E+TSA^(θ→)(E^p0=I^)E^piFobj(θ→)=S(high-Tlimit)P=Tr[ρC2]Fobj(P,E)=E−TP=E−TTr[ρC2]θ→A^(θ→)|Ψ⟩T=A^(θ→)|Φ⟩θ→gA^g=A^(θ→g)E^piA^(θ→g)E^piθ→eiA^ei=E^piA^(θ→ei){A^ei}H^∈ℂ2n×2n|ψT(k)⟩=∑iαi(k)|λi⟩{Ξ(k):={θ→j}}maxφ→∈Ξ(k)‖φ→−Eθ→∈Ξ(k)(θ→)‖max≤xmaxO(NiterNdim(θ→)(‖H^‖2mink∑i|αi(k)|4+T2)[Γδ]2+1ϵ){ϵμ2(k)}{ϵΣ4(k)}Γ:=maxk(xmax(k)/ϵμ(k),xmax2(k)/ϵΣ2(k))E^piH^=H^0+V^H^0=∑iϵia^i†A^iV^a^i†A^jE^p=exp[π/2(a^i†A^j−a^j†A^i)](|20⟩+|02⟩)/2(|1010⟩+|0101⟩)/212(|0⟩C⊗I^|Ψ⟩T⊗|0⟩P+|1⟩C⊗U^|Ψ⟩T⊗|1⟩P)12(|0⟩C⊗I^|Ψ⟩T+|1⟩C⊗U^|Ψ⟩T)A^=eiφaeiφbσ^z/2eiφcσ^y/2U^=eiφcσ^z/2eiφdσ^y/2eiφeσ^z/2H^=(α−ℓ)I^+βσ^xE^p=eiπσ^z/2U^2kH3+E^piH3+(H2,H3+,H3,H4)E^piH^∈ℂ2n×2nO(Niterκ2pΛ2dim(θ→)(‖H^‖2mink∑i|αi(k)|4+T2)[dim(θ→)δ]2p+4(p+1)+1ϵ)H^=H^0+V^H^0=∑ijhijbi†bjV^H^0=F^V^H^0=∑iϵiai†aiai†ajV^{ai†aj|Ψ⟩}E^ij(θ)=exp[θ(ai†aj−aj†ai)]Dij=⟨Ψ|ai†aj|Ψ⟩ci†cjH^0=F^e−iH^t≈e−iP^1te−iP^2t⋯P^1,P^2,…H^H^=(αββα)H^qubit=αI^+βσ^xI^σ^xH^′=H^−ℓI^H3+U^(t→)=exp[i(∑ijtij(ai†aj)+∑ijkltijkl(ai†aj†akal))]ai†U(t→)U^(t→)=
exp[∑ijtij(ai†aj−aj†ai)+∑ijkltijkl(ai†ajak†al−al†akaj†ai)]A^(θ→)A^(θ→)=
exp[(∑iθiA^i)t]Eij= exp[π2(ai†aj−aj†ai)]H3+H3+H3+E^p3dim(θ→)

20) I For j=1□n If s j=∗ o SOLVEψ[x,t]=e−iHt[∫0teiHt∫W[x,t∫]dt∫+ψ[x,t0]]∫0δteiHt∫W[x,t∫]dt∫∫12[eiHδt, |+⟩=[|0⟩+|1⟩]/2 |Q⟩≡M1⊗⋯⊗Mm|G⟩ f[x1,x2]=eax1x-2+bx1+cx2 Mj†Mj=λ1|+⟩⟨+|+λ2|−⟩⟨−| |±⟩=[|0⟩±|1⟩]/2 eax1x2−ax1/2−ax2/2 d1[x1] d2[x2] d1[x1]d2[x2][λ1δx1x2+λ2[1−δx1x2]]/2 d[x] |±⟩=[|0⟩±|1⟩]/2 D1= diag[d1[0],d1[1]] D2=diag[d2[0],d2[1]] Σyp[x,y|z]=⟨Q[z]|O|Q[z]⟩⟨Q[z]|Q[z]⟩ O1=[∂θiMi]Mi−1+H.c. O2=|vi⟩⟨vi|[∂θiMi]Mi−1+H.c. |Qt−1⊥⟩,|Qt⊥⟩ |Qt⊥⟩ |Qt⊥⟩ |Qt−1⊥⟩ |Qt⊥⟩ O[n] O[nc+1]O[nc]O~[n2c/Δ]O~[⋅]term[k]=1−[1−ηt][ηt2+[1−ηt]2]kO~[n2c+1/[ηΔε]]T=O~[n2c+2/[ηΔεδ]]|ψhistory⟩=1T+1Σt=0T|t⟩⊗Vt⋯V1|0⟩⊗m a [i] = [j ∈ V 2 a v e r t e x j i n t h e s e c o n d n e t w o r k − a g a p . s [a] = Σ i ∈ V 1 a [i] ≠ − σ [i, a [i]] + Σ i ∈ V 1 a [i] ≠ − Σ k ∈ V 1 a [k] ≠ − τ [i, a [i], k, a [k]], τ [i, j, k, l] = [1 for [i, k] ∈ E 1 and [j, l] ∈ E 2

0 otherwise . s [M] = Σ [i, j] ∈ M σ [i, j] = Σ [i, j] ∈ M Σ [k, l] ∈ M [k, l] > [i, j] τ [i, j, k, l] . max ⍰ Σ [i, j] ∈ V 1 × V 2 σ [i, j] x i j + Σ [i, j] ∈ V 1 × V 2 Σ [k, l] ∈ V 1 × V 2 τ [i, j, k, l] x i j x k l s . t . Σ [i, j] ∈ δ [v] x i j ≤ 1 ∀ v ∈ V 1 ∪ V 2 max ⍰ Σ [i, j] ∈ V 1 × V 2 σ [i, j] x i j + Σ [i, j] ∈ V 1 × V 2 Σ [k, l] ∈ V 1 × V 2 τ [i, j, k, l] y i j k l s . t . Σ [i, j] ∈ δ [v] x i j ≤ 1 ∀ v ∈ V 1 ∪ V 2 y→ijkl y→klij τ→ τ → [i, j, k, l] + τ → [k, l, i, j] = τ [i, j, k, l], τ→[i,j,k,l]=τ→[k,l,i,j]=τ[i,j,k,l]2 max ⍰ Σ [i, j] ∈ V 1 × V 2 σ [i, j] x i j + Σ [i, j] ∈ V 1 × V 2 Σ [k, l] ∈ V 1 × V 2 τ → [i, j, k, l] y → i j k l s . t . Σ [i, j] ∈ δ [v] x i j ≤ 1 ∀ v ∈ V 1 ∪ V 2 y → i j k l ≤ x i j ∀ [i, j, k, l] ∈ [V 1 × V 2] 2 y → i j k l = y → k l i j ∀ [i, j, k, l] ∈ [V 1 × V 2] 2 y → i j k l ∈ [0, 1] ∀ [i, j, k, l] ∈ [V 1 × V 2] 2 y→ y→ijkl y→ijkl max ⍰ Σ [i, j] ∈ V 1 × V 2 σ [i, j] x i j + Σ [i, j] ∈ V 1 × V 2 Σ [k, l] ∈ V 1 × V 2 τ → [i, j, k, l] y → i j k l + Σ [i, j] ∈ V 1 × V 2 Σ [k, l] ∈ V 1 × V 2 λ i j k l [y → i j k l − y → k l i j] s . t . Σ [i, j] ∈ δ [v] x i j ≤ 1 ∀ v ∈ V 1 ∪ V 2 y → i j k l ≤ x i j ∀ [i, j, k, l] ∈ [V 1 × V 2] 2 y → i j k l ∈ [0, 1] ∀ [i, j, k, l] ∈ [V 1 × V 2] 2 max ⍰ Σ [i, j] ∈ V 1 × V 2 σ [i, j] x i j + Σ [i, j] ∈ V 1 × V 2 Σ [k, l] ∈ V 1 × V 2 [τ → [i, j, k, l] + λ i j k l] y → i j k l . y→ijkl τ→ σ [i, j],

21) MAKEx,x=Mi+k,i=0,…,M−1,k=0,…,M−1}|χ(πS)||χ(πS)|=maxk=0,…,M−1∑x=0M−1(χik(ρA,σk))Mx+k,∑y=0M−1(χik(ρA,σk))Mk+y,|χ(πS)|≤1⟨ζ□(πS),ZRj(πS)⟩−⟨χ(πS),ZRj(πS)⟩≥0 L(ZRj(πS))ZRj(πS)L(ZRj(πS))=∑i,k(ZRj(πS)((Ri,σk)))2.E(L(ZRj(πS′))−L(ZRj(πS))|ZRj(πS))≤−ε|ZRj(πS)|,ZRj(πS)ε>0πSγ(πS)=0Rjω^(πS)S^(Rj)f(γ(πS))=0ω^(πS)≤ω∗(πS).γ(πS)>0ζ(πS)≠ζ∗(πS)ω∗(πS)ω(γ(πS))=maxζ(πS)⟨ζ(πS),ZRj(πS)⟩<ω∗(πS),γ(πS)ω∗(πS)ω(γ(πS))<ω∗(πS)ω(γ(πS))≥ω∗(γ(πS)=0)−f(γ(πS)),f(⋅)0≤f(γ(πS))<c(γ(πS)),limγ(πS)→∞f(γ(πS))γ(πS)=0,γ(πS)≥γ(πS=0)c>0E(L(ZRj(πs′))−L(ZRj(πS))|ZRj(πS))≤−ε,ε>0■ζ(πS)γ(πS)>0S(Rj)γ(πS)>0πSζ(πS)S(Rj)L(X)

22) EVALUATE((Ri,σk))i=1,…,Nk=1,…,MZRj(πS)((Ri,σk))≥0SI(Rj)SO(Rj)RjSI(Rj)SO(Rj)USω(γ(πS))S(Rj)γ(πS)>0γ(πS)πSS∗(Rj)γ(πS)=0ω(γ(πS)=0)=ω∗(πS)πSS(Rj)ω(γ(πS))≥ω∗(πS)−f(γ(πS))ω(γ(πS))<ω∗(πS)S^(Rj)ω^(πS)≤ω∗(πS)πSζik(ρA,σk)ζik(ρA,σk)=1,ifρA∈SRj(πS)((Ri,σk))0,otherwise,ζik(ρA,σk)=1ρASRj(πS)((Ri,σk))σkζ(πS)=ζik(ρA,σk)i≤N,k≤NRjπSZRj(πS)((Ri,σk))ω(πS)ζ(πS)πSω(πS)=∑i,kζik(ρA,σk)ZRj(πS)((Ri,σk))=⟨ζ(πS),ZRj(πS)⟩,⟨⋅⟩

23) UPDATE TO THE RjdABd=2|β00⟩AB|β00⟩=12(|00⟩+|11⟩)),σABσF=⟨β00|σ|β00⟩,F≥0.98σF′Fin<F′≤1,FinBF(ELli)LlELlidELliFd=2ELliCc:BF(ELli)≥BF□(ELli),for∀i,BF□(ELli)FELliBF(ELli)ELliBF□(EL

li)jRjρ|β00⟩=12(|00⟩+|11⟩)Rj−1σRj|β00⟩Rj+1USjRjρσRj−1Rj+1CtC=1/fCoCRjfCoCπSSI(Rj)=∪iρiUSSO(Rj)=∪iσiπS=xtCxSI(Rj)SI∗(Rj)SI(Rj)Q=∑i=1N|Bi|πSRjNRj|Bi|iπSSI(Rj)=∪i=1Qρi|SI(Rj)|=QSO(Rj)SO∗(Rj)SO(Rj)NRjπSSO(Rj)=∪i=1Nσi|SO(Rj)|=NS(Rj)RjS(Rj)=SI(Rj)∪SO(Rj).S(Rj)S∗(Rj)S∗(Rj)=SI∗(Rj)∪SO∗(Rj),|S∗(Rj)|=Q+N.S(Rj)S(Rj)|S(Rj)|<Q+N.S∗(Rj)Sˆ(Rj)=SˆI(Rj)∪SˆO(Rj)πS|Sˆ(Rj)|=N+NπSSRj(πS)((Ri,σk))SI(Rj)RjRiσkSO(Rj)ZRj(πS)((Ri,σk))=|SRj(πS)((Ri,σk))|.|B(Ri(πS),σk)|RiσkπSZRj(πS′)((Ri,σk))ZRj(πS′)((Ri,σk))=ZRj(πS)((Ri,σk))+|B(Ri(πS),σk)|,πS′ρσPr(ρ,σ)=x≥0|BRi(πS)|RjπS|BRj(πS)|=∑i,k|B(Ri(πS),σk)|,|B(Ri(πS),σk)|RiσkπS|BRi(πS)||BRj′(πS)|Rj|BRj′(πS)|=1−LN11+D(πS)(|BRj(πS)|),L0<L≤ND(πS)πS SI(Rj)SO(Rj)RjRjζ(πS)Rjε>0B>0limπS→∞Pr(|SI(πS)(Rj)|>B)<ε,SI(πS)(Rj)RjπS|SI(πS)(Rj)|RjSI(πS)(Rj)ζ(πS)RjlimπS→∞supE(|SI(πS)(Rj)|)<∞.γ0≤γ≤1γ=0πSS∗(Rj)γ>0S(Rj)πSγSI(Rj)SO(Rj)πSSˆ(Rj)|SˆI(Rj)|=N|SˆO(Rj)|=N|Sˆ(Rj)|=N+N=2NZRj(πS)((Ri,σk))SRj(πS)((Ri,σk))i=1,…,Nk=1,…,NZRj(πS)((Ri,σk))=1S∗(Rj)|SI∗(Rj)|=Q>N|SO∗(Rj)|=N|S∗(Rj)|=Q+NSRj(πS)((Ri,σk))i=1,…,Nk=1,…,NZRj(πS)((Ri,σk))≥1S(Rj)SI(Rj)|S∗(Rj)|=Q′+MQ′≤QM=N−LLπSSRj(πS)((Ri,σk))σkπSSO(Rj)|SO(Rj)|=MSRj(πS)((Ri,σk))i=1,0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000…,

24) STORE_(vi=[vi1,vi2…viD])(xi=[xi1,xi2…xiD])(pbesti=[pbesti1,pbesti2…pbestiD])vid(t+1)=w×vid(t)+c1r1×(pbestid−xid(t))+c2r2×(gbestd−xid(t)),xid(t+1)=xid(t)+vid(t+1),vid(t+1)=w×vid(t)+c×rid×(pbestf(i,d)d−xid(t)),(soli=[soli1,soli2…soliD])solid=solid+ε(solr1d−solr2d),xid=pbestid+ε×(pbestr1d−pbestr2d),pbestidpbestf(i,d)dxid=pbestf(i,d)d+ε×(pbestr1d−pbestr2d),pbestf(i,d)dpbestf(i,d)dpbestf(i,d)ds={|Ubd−Lbd|,rand2<0.5,‖pbestr1−pbestr2‖,otherwise,pbestf(i,d)d=pbestadpbestf(i,d)d=pbestbdxid=pbestf(i,d)d+ε×(pbestr1d−pbestr2d)F1(x)=∑d=1D(∑j=1dxj)2F2(x)=x12+106·∑d=2Dxd2F3(x)=418.9829·D−∑d=1Dg(zd),zd=xd+4.209687462275036e2g(zd)={zdsin(|zd|1/2)(500−mod(zd,500))sin|500−mod(zd,500)|−(zd−500)210000D(mod(|zd|,500)−500)sin|mod(|zd|,500)−500|−(zd+500)210000DF5(x)=∑d=1D−1(100(xd2−xd+1)2+(xd−1)2)F6(x)=∑d=1D(xd2−10cos(2πxd)+10)F7(x)=10D2∏d=1D(1+d∑j=1322ixd−round(2ixd)2i)10D1.2−10D1.2F8(x)=g(x1,x2)+g(x2,x3)+…+g(xD,x1)where g(x,y)=0.5+(sin2(x2+y2)−0.5)(1+0.001(x2+y2))2F9(x)=g(F5(x1,x2))+g(F5(x2,x3))+…+g(F5(xD,x1))where g(y)=∑d=1Dyd24000−∏d=1Dcos(ydd)+1F17(x)=g(x)+fbias4,z=M(x−o),fbias4=200g(y)=106·y12+∑d=2Dyd2(k1∗,k2∗…kD∗)=argk0<k1<…<kd<…kD+1max{F(k1,k2…kD)},F=∑d=0Dωd(μd−μT)2μd=∑l=kdkd+1l·Plωdωd=∑l=kdkd+1PlμT=∑l=1Ll·Pl SIVIRINAVIRTM

25) END

Table1b. SIVIRINAVIRTM Spectrum Fragments Generated

OUTPUT: SIVIRINAVIRTM Spectrum			
energy0			
15.02292652	1.42932195	133	1.4293
17.03857658	0.6643665492	132	0.66437
57.04472458	0.5109772679	25	0.51098
59.06037464	1.510803429	24	1.5108
73.07602471	1.485964482	26	1.486
89.07093933	0.9070527015	40	0.90705
90.01032683	0.6806474081	108 64	0.61574 0.06491
92.02597689	1.133331982	12	1.1333
107.0368759	0.8272843188	63	0.82728
116.0818384	5.244322576	2	5.2443
118.0974884	2.050475049	29	2.0505
131.0927374	4.238134601	37	4.2381
133.1083875	11.25406234	45	11.254
134.047775	0.6688143224	84	0.66881
148.063425	0.8481598948	62	0.84816
257.1525744	0.9895674005	55	0.98957
272.171716	0.612458317	59	0.61246
274.1791235	0.4908505044	54	0.49085
400.3030645	0.5015678839	73	0.50157
412.3030645	9.345580922	87	9.3456
414.3187146	0.487653516	101	0.48765
439.3139635	0.8239264709	110	0.82393
441.3296136	3.076704898	111	3.0767
454.3248626	3.135510573	139	3.1355
456.3405126	16.1689173	141	16.169
458.3561627	1.349038772	154	1.349
513.3061149	0.5608236674	106	0.56082
518.332664	0.7986662784	194	0.79867
529.3486484	0.7277352701	5 158	0.58258 0.14515
530.332664	15.07621006	162 104 1	12.918 1.8518 0.30635
547.3592131	12.4010693	0	12.401
547.3592126635301	12.4010693		

Structure	ID		Mass	SMILES
	0		547.35921 31	NC(CN1CCCC(C2=CCOCC(NN3CCCN([NH3+])C3O)NCCO2)CCNC1)N=P1(O)CC1N
	2		116.08183 84	[NH3+]N1CCCNC1=O



Fig.2b SivirinavirTM_(2DStructure)_PreferredIUPACName=1-amino-3-{[(8E)-8-(1-{2-amino-2-[(2-amino-1-hydroxy-1lambda5-phosphiran-1-ylidene)amino]ethyl}-1,3-diazonan-6-yl)-2,3,4,5,6,10-hexahydro-1,7,4-dioxazecin-3-yl]amino}-1,3-diazinan-2-ol

Rank	Compound	Score	T. Energy	I. Energy
1	ligand_96a60ad1ee_1	-6.139	910339.768	-38.313



Figure No.3 3D Docking Interactions of the SivirinavirTM_1XAK_5e76098ea2a80 small molecule inside the PDB:1XAK STRUCTURE OF THE SARS-CORONAVIRUS ORF7A ACCESSORY PROTEIN binding domains with some of 910339.768 Docking T.Energies.

SivirinavirTM_1XAK_	Model	T.Energy	I.Energy	vdW	Coul	NumRotors	RMSD	Score
ligand___run_9.	1	910339.768	-38.313	3.698	-42.011	8	0.000	-6.139
ligand___run_6.	2	910345.222	-30.069	1.741	-31.810	8	7.011	-6.076
ligand__run_1.	3	910345.635	-32.620	1.640	-34.260	7	2.304	-5.971

Table 2. Docking Energy values of the SivirinavirTM drug design within the PDB:1XAK STRUCTURE OF THE SARS-CORONAVIRUS ORF7A ACCESSORY PROTEIN binding domains.

RESULTS AND DISCUSSION

The Cancer Drug Repurposing for Advanced Quantum Back-Action- Particle-Swarm-Optimization Fragment-Evading Measurements routing scheme is based on the fundamentals of $x'\alpha=m1\alpha TK1x,x'\alpha+m2\alpha TK2x,x'\alpha+\cdots+mU\alpha TKUx,x'\alpha\geq 0$. Swarm intelligence in order to find the optimal shortest path of the pendant edges (virtual edges) in entangled quantum networks. In this research paper we defined the terms of entanglement utility between isolated FDA cancer drug and connected drugs and path entanglement gradient and proposed the routing metrics from available external SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 paramaterized Schrodinger-inspired physarum-prize-collecting Neural Matrix Factorization drug repositioning docking system.sources. The routing metrics of a anchoring set of vi, $SiA=\{vj|vi\in SD,vj\in Sc,vi\sim vj\}$ are derived from the characteristics of entangled links, where vi~vj is identified throughput entanglement capabilities, and the distribution of the entangled states from available external sources of vi, $SiV=Sc\backslash SiA$. The method allows for moderate complexity routing anchored to {dr2, dr3, dr5} based on quantum repeater networks by fusing the anchoring set SA = {dr2, dr3, dr5} of the connectable drugs with relevant characteristics of entanglement distribution and swarm intelligence theory to select connectable drugs from anchoring set SA. The scheme can be directly applied in quantum graph-based semi-supervised learning (SSL) SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 paramaterized Schrodinger-inspired physarum-prize-collecting Neural Matrix Factorization drug repositioning docking system networking, future quantum virtually connected graph Internet, and experimental long-distance quantum communications f = {f1, f2, …fn}T when a disconnected drug is given.

In this study we generated Docking Algorithms to be connected to the graph for the:

-Experimental quantum simulation based on scoring results and Distributed Network Considering Distributed Generations determined by scores on anchored SARS-CORONAVIRUS ORF7A drugs on Mapping nonlinear gravity into General Relativity by descending order of scores f and it connects vi to vj ’s with nonlinear electrodynamics using validation set SV to preserve the network’s property via boson exchange in a trapped ion which means that the connecting step prevents the degradation of SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 paramaterized Schrodinger-inspired physarum-prize-collecting Neural Matrix Factorization drug repositioning docking system. network’s performance Docking Algorithms.

-Machine Learning drug network construction for the SARS-CORONAVIRUS ORF7A System for Phenotype SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 Data Acquisition and drug scoring Direct quantum process Analysis via Quantum Walks based Quantum Hash Function by calculating similarity for metabolic scaling in self-similar asymmetric networks based on shared drug-target SARS-CORONAVIRUS ORF7A protein measuring sequential weak values of incompatible observables Docking Algorithms.[87-100]

-Performance of Source Localization Estimations to increase the number of nodes and edges of Fractional- Order Chaotic Systems by Using Quantum Parallel Particle Swarm SARS-CORONAVIRUS ORF7A network complementation algorithm Optimization Merging Algorithms from PubChem and PubMed as reflected to the network on the Extraction of gravitational waves leading to higher and more stabilized performance in numerical relativity in Feature Selection and Predictors of Falls with Foot Force Sensors Using KNN-Based Docking Algorithms. [91-101]

- Multiscale Quantum Harmonic Oscillator for the Numerical observation of emergent spacetime supersymmetry at quantum criticality simple quantum voting scheme with multi-qubit entanglement Docking Algorithms to Distributed Network Considering Distributed Generation Artificial fish complete Update and obtain the optimal value mainly through the following four behaviors: being random, preying, swarming, and following in the process of iterative calculation on Small Molecules against the SARS-CoV-2: the Mpro, the PLpro, and the S-protein as Rotating stars in relativity Improved Quantum Simulations. [96-104]

- Artificial Fish Docking Algorithm to develop a highly accurate SO = {vi| vi ∈ V, i = 1, … , n}, set of connected drugs Sc = {vi| vi, vj ∈ SO, ∃j vi~vj}, polarizable novel Nano-ligand targeted to the regulation of the SARS-CORONAVIRUS ORF7A,

NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 parameterized Schrodinger-inspired physarum-prize-collecting Neural Matrix Factorization drug repositioning docking system. Then we further removed another 10 proteins from the list as there is no structure for and set of isolated (disconnected) drugs SD = {vi| vi, vj ∈ SO, ∀j vi ≁ vj} either SARS-CoV-2 or SARS. Among the 16 proteins left, S protein and nsp5 of SARS-CoV-2 have structures deposited in the Fg y = V b e s t t : m a x ⁡ g e n − VAv e r a g e t : m a x ⁡ to maintain the properties of the original network of SARS-CoV-2 protein data bank (PDB) with PDB ID 6CS2 and 6LU7, g e n 2 = V b e s t t − VAv e t 2 + V b e s t t + 1 −V A v e t + 1 2 + ⋯ + V b e s t m a x ⁡ respectively. Not surprisingly, two structures show little g e n − V A v e m a x ⁡ g e n 2 m a x ⁡ g e n − t + 1 ,αTKmixx,x′α structural variation compared with their SARS counterparts. To enhance the network, we apply a complementation 12w2+CΣi=1lξis.t. algorithm, which reinforces a network the remaining 14 viral proteins which share high sequence identities while preserving the original minα 12Σi−1l Σj=1lyiyjKxi,xjαiαj−Σj=1lαjs.t. source with their SARS counterparts, Σi=1lyiαi=0,0≤αi≤C, i=1,2,…,l. ranging from 76.60% in (y1y2yp)=f((w01w02…w0nw11w12…w1pwp1wp2…wpn)•(1x1xn)). nsp3 to 99.84% in nsp13, with nsp4 as the only exception. The high b=yj−Σi=1lyiαiKxi,xj.gx=Σi=1lαiyiKxi,xj+b. Kpolyx,y=xty+1dKrbfx,y=exp⁡−x−y22g2, Kmixx,x′=Σp=1UmpKpx,x′, sequence identities ensure the D={(xi,yi) | xi∈ℝP,yi∈{−1,1}}i=1n. reliabilities of homologous structures for initializing ωk=ωend+ωstart−ωendTmax−kTmax connections using SARS proteins as templates. Nsp4, whose template was using homologous structure of mouse hepatitis virus A59 on nodes, scoring step for determining priority (61.36% sequence identity to nsp4 of SARS-CoV-2), has no other close homology:e-iHmeas.Δt= Σje-iεjΔtεjεj, Hmeas.″= ΣjεjΔtmod2πεjεj Hmeas.″ Hmeas.″ Umeas.ψE0,0= ΣE′,E″aE,E′,E″ψ E′E″θ(E,E′,E″). δE·T(n)∈Ω1poly(n). H= Σi=0nσiz. UN,yx=x·ymodN0≤x<Nxotherwise HN,y=UN,y+UN,y†UN,ytUSEEMψE0,0=ψE(vi=[vi1,vi2…viD])(xi=[xi1,xi2…xiD])(pbesti=[pbesti1,pbesti2…pbestiD])vid(t+1)=w×vid(t)+c1r1×(pbestid−xid(t))+c2r2×(gbestd−xid(t)),xid(t+1)=xid(t)+vid(t+1),vid(t+1)=w×vid(t)+c×rid×(pbestf(i,d)d−xid(t)),(soli=[soli1,soli2…soliD])solid=solid+ε(solr1d−solr2d),xid=pbestid+ε×(pbestr1d−pbestr2d),pbestidpbestf(i,d)dxid=

pbestf(i,d)d+ε×(pbestr1d−pbestr2d),pbestf(i,d)dpbestf(i,d)dpbestf(i,d)ds={|Ubd−Lbd|,rand2<0.5,‖pbestr1−pbestr2‖,otherwise,pbestf(i,d)d=pbestadpbestf(i,d)d=pbestbdxid=pbestf(i,d)d+ε×(pbestr1d−pbestr2d)F1(x)=∑d=1D(∑j=1dxj)2F2(x)=x12+106·∑d=2Dxd2F3(x)=418.9829·D−∑d=1Dg(zd),zd=xd+4.209687462275036e2g(zd)={zdsin(|zd|1/2)(500−mod(zd,500))sin|500−mod(zd,500)|−(zd−500)210000D(mod(|zd|,500)−500)sin|mod(|zd|,500)−500|−(zd+500)210000DF5(x)=∑d=1D−1(100(xd2−xd+1)2+(xd−1)2)F6(x)=∑d=1D(xd2−10cos(2πxd)+10)F7(x)=10D2∏d=1D(1+d∑j=1322ixd−round(2ixd)2i)10D1.2−10D1.2F8(x)=g(x1,x2)+g(x2,x3)+…+g(xD,x1)where

g(x,y)=0.5+(sin2(x2+y2)−0.5)(1+0.001(x2+y2))2F9(x)=g(F5(x1,x2))+g(F5(x2,x3))+…+g(F5(xD,x1))whereg(y)=∑d=1Dyd24000−∏d=1Dcos(ydd)+1F17(x)=g(x)+fbias4,z=M(x−o),fbias4=200g(y)=106·y12+∑d=2Dyd2(k1∗,k2∗…kD∗)=argk0<k1<…<kd<…kD+1max{F(k1,k2…kD)},F=∑d=0Dωd(μd−μT)2μd=∑l=kdkd+1l·Plωdωd=∑l=kdkd+1PlμT=∑l=1Ll·Pl

ΣE′aE′E′,θ(E′), H= ΣjHj, H= Σi,jmAi,jai†aj+12ΣijBi,jaiaj+12Σi,jBj,i*ai†aj†A=A†,B=B†ai†,ai mn PrE′E-E′≤δE≥η. δE·T(n)∈1poly(n) {Hn}n=1∞ {Un}n=1∞ {Un}n=1∞ ΔE≤ηδE+21-ηH (1-e-m21-12η2,δE,mβ) ψt=2-n⁄2 Σy=12ny⊗Uty, 1T Σt=0T-1t U=1-2ωω·2N(N-1s′s′+ωω+N-1s′ω+ωs′)-1, s=(N- 1)⁄Ns′+1⁄Nω U=1NN-2-2N-12N-1N-2=1cos2N-1N-isin2N-1Nσy+ON-3⁄2=e-2iN-1Nσy+ON-3⁄2. 1-2N+ON-2=cos2N-1N 2N-1N+ON-3⁄2=sin2N-1N. H=2σy⁄N 12s′±iω e-iH-U=e-2iσy⁄N-e- 2iσyN-1⁄N+ON-3⁄2=ON-1. 1⁄N N-e-2iσyN-1⁄N+ON-3⁄2=ON-1. E(H)=U(H⊕p⊕H¯⊕q)U† H¯ V(H⊗P+H¯⊗Q)V† E~(H)=V~(H⊗P+H¯⊗Q)V~† E~(1)=P≤Δ(H′) ‖V~−V‖≤η ‖H≤Δ′− E~(H)‖≤ϵ H≤Δ′=P≤Δ(H′)H′ E~ E~ |ZH′(β)−(p+q)ZH(β)|(p+q) ZH(β)≤dm−ne−βΔ(p+q)e−β‖H‖+(eϵβ−1). Estate(N(ρ))=N′(Estate(ρ))+O(η), H′=H⊗|+y{+H¯⊗|−y} |±y}=(|0{±i|1})/2ΔtΔE≥12 Hmeas.′=cHmeas. e-iHmeas.Δt= Σje-iεjΔtεjεj, Hmeas.″= ΣjεjΔtmod2πεjεj Hmeas.″ Hmeas.″ Umeas.ψE0,0= ΣE′,E″aE,E′,E″ψ E′E″θ(E,E′,E″). δE·T(n)∈Ω1poly(n). H= Σi=0nσiz. UN,yx=x·ymodN0≤x<Nxotherwise HN,y=UN,y+UN,y† UN,yt USEEMψE0,0=ψE ΣE′aE′E′,θ(E′), H= ΣjHj, H= Σi,jmAi,jai†aj+12ΣijBi,jaiaj+12Σi,jBj,i*ai†aj†A=A†,B=B†ai†,ai mn PrE′E-E′≤δE≥η. δE·T(n)∈1poly(n) {Hn}n=1∞ {Un}n=1∞ {Un}n=1∞ ΔE≤ηδE+21-ηH (1-e-m21-12η2,δE,mβ) ψt=2-n⁄2 Σy=12ny⊗Uty, 1T Σt=0T-1t U=1-2ωω·2N(N-1s′s′+ωω+N-1s′ω+ωs′)-1, s=(N- 1)⁄Ns′+1⁄Nω U=1NN-2-2N-12N-1N-2=1cos2N-1N-isin2N-1Nσy+ON-3⁄2=e-2iN-1Nσy+ON-3⁄2. 1-2N+ON-2=cos2N-1N 2N-1N+ON-3⁄2=sin2N-1N. H=2σy⁄N 12s′±iω e-iH-U=e-2iσy⁄N-e- 2iσyN-1⁄N+ON-3⁄2=ON-1. 1⁄N 1⁄N. We apply our formalism to the situations for all energy contributions by connecting two or more repurposed cancer FDA drugs and its polarizable fragments that previously have no connection in which

the reference frames are related via ‘superposition of translations’ and ‘superposition of Galilean boosts’, and formulate an extension of the weak equivalence principle for such quantum reference frames, including electronic polarization, charge transfer and covalent-bond formatted high energy scaffolds. This work has been carried out within Galilean relativity, selecting candidates in terms of their QMDS however the framework is general and can be applied in a special-relativistic key interaction or in a general-relativistic context with the receptor, and visual inspection. This would lead to interesting insights as to, for instance, the flow of proper time when there is no classical worldline describing the motion of the system serving as reference frame. More specifically, our formalism could be able to describe situations, such as those studied in refs. 31–33, in which clocks—quantum systems with internal degrees of freedom—move in superpositions of classical wordlines in the gravitational field.[96-163] Independently, in this in silico drug design work-based estimate for ln[ρx[x]/π[x]] we used in the expensive drug repurposed lower bound [Table1] could be useful for other analyses to construct the Cancer Drug-Drug Relation regression and clustering SARS-CORONAVIRUS ORF7A matrix. For example, an estimate of ln[ρx[x]/π[x]] could be used to interpret which can be viewed as a type of kernel matrix what features of x are most distorted by integrator bias, e.g., by checking which features are combined and the consensus clustering of x are most predictive of extreme values of ln[ρx[x]/π[x]] as an input for kernel classification.

CONCLUSION

To answer this question, we estimated the GHMC acceptance rate at all conditions for which we have estimated steady state 𝒟KL. This allows us to avoid assuming the existence of an ‘external’ perspective of an absolute reference SARS-CORONAVIRUS ORF7A, NSP5 OF SARS-COV-2, PDB ID 6CS2 AND 6LU7 docking, fragmenting, recoring and pharmacophoric merging frame. We find transformations between quantum reference frames, and show how the state, the dynamics, and the measurement change under these transformations. We show that the notion of entanglement and superposition as observer-dependent features, and re-wrote the Schrödinger equation in quantum reference frames’(H)=U(H⊕p⊕H¯⊕q) [C]1=C2C3C12C12C=NC45CC4C54C1[N+]324U† H¯E(H)=V(H⊗P+H¯⊗Q)V†COC1C(O)=C2C34N=[C]C5=[N+]6C5(O)C63C214E~(H)=V ~(H⊗P+H¯⊗Q)V~†betweenvectorheadsdonor/acceptorE~(1)=P≤Δ(H′)‖V~−V‖≤ηNN1C=C

CN([NH3+])C1[NH3+]N1CCCN(N=C2COCCC(C3CCCNCNCC3)OCC=N2)C1NC(CN1CCC=C(C2=CCOCC(=NN3CCCN([NH3+])C3)N=CCO2)CCNC1)NP1(O)CC1NC(CN1CCCC(C2CCOCC(=[NH2+])N=CCO2)CCNC1)NP1(O)CC1NCOC1C(O)=C2C34N=CC5=[N+]6C5(O)C63C214‖H≤Δ′−E~(H)‖≤ϵH≤Δ′=P≤Δ(H′)H′E~E~|ZH′(β)−(p+q)ZH(β)|(p+q)ZH(β)≤dm−ne−βΔ(p+q)e−β‖H‖+(eϵβ−1).Estate(N(ρ))=N′(Estate(ρ))+O(η),H′=H⊗|+y{+H¯⊗|−y}C1C2[CH2+]C12 [CH+]1[C]2CC12|±y}=(|0{±i|1})/2 ΔtΔE≥12 Hmeas.′=cHmeas. e-iHmeas.Δt= Σje-iεjΔtεjεj, Hmeas.″= ΣjεjΔtmod2πεjεj Hmeas″Hmeas″ for averaging: four threshold distancesbetweendifferentpharmacophorefeaturesUmeas.ψE0,0=ΣE′,E″aE,E′,E″ψE′E″θ(E,E′,E″)δE·T(n)∈Ω1poly(n).H=Σi=0nσiz.UN,yx=x·ymodN0≤x<NxotherwiseHN,y=UN,y+UN,y†UN,ytC[OH+]CCOUSEEMψE0,0=ψEΣE′aE′E′,θ(E′),H=ΣjHj,H=Σi,jmAi,jai†aj+12ΣijBi,jaiaj+12Σi,jBj,i*ai†aj†A=A†,B=B† ai†,ai mnPrE′E-E′≤δE≥η.δE·T(n)∈1poly(n) {Hn}n=1∞ {Un}n=1∞ {Un}n=1∞ ΔE≤ηδE+21-ηH (1-e-m2112η2,δE,mβ)ψt=2n⁄2Σy=12ny⊗Uty,1T[C]1=C2C3C12C12C=NC45C=C4C54C1[N+]324. We also yield the two-dimensional Poisson distribution, about the derivation is specific to the partition matching the primary objective of heterogeneous/multi-view integrable limit of the SARS-CORONAVIRUS ORF7A system, by employing Jaccard similarity between configuration docking fitness scoring degrees equals the distribution obtained from the complex Ginibre ensemble, or squared Euclidean distance of freedom and velocities to obtain a consensus SARS-CORONAVIRUS ORF7A novel drug design solution. We could also use this method to measure the KL divergence or taking the average distance over any subset S of the state variables z = [x, v], provided we can sample from the conditional distribution for the complementary subset S of the state variables: π[zS |zS]. To measure KL divergence over the configuration variables, [112-164], clustering algorithms we need only sample from the conditional distribution based on multiple metrics of velocities given positions, in clustering drugs which is typically tractable as well as their corresponding features. Provided that the required conditional distribution could potentially hinder the efficiency to higher dimensional feature space[113-164], to present in more than one cluster in this method could also prove useful in pharmacology data contexts other than measuring integrator error. Finally, in this study, describing the fully chaotic limit of multiple links connecting cancer fragmented drugs we have only considered sampling the canonical ensemble generalizing the results of Grobe, Haake, and Sommers, [114-164], [NVT; constant temperature, docking fitness scoring, and docking energy], but the isothermal-isobaric ensemble [NpT; constant temperature, particle

number, and pressure] also has wide practical relevance. In BiogenetoligandorolTMOpenMM, who derived a universal cubic level repulsion the isothermal-isobaric ensemble is simulated by alternating for small spacings s between sampling the canonical ensemble [using thermostatted dynamics, such as Langevin dynamics], and periodically sampling the volume using a molecular-scaling Monte Carlo barostat. In [117-164], the error in phase space was measured for an ensemble of constant-volume Langevin trajectories with initial conditions drawn from the isothermal-isobaric ensemble. In this study, we denoted the verified drug-disease associations tuning the parameters as positive samples, by the clusters while the remaining unverified associations were considered as negative samples. For each specific threshold, we calculate the Quantum visibility corresponding true positive (TP), true negative (TN), false positive (FP), and false negative (FN) as a witness of general optimizing clusters for NMI and SMI relativistic proper time docking values. If a test association's corresponding score is greater than the threshold, it was labeled as a positive sample. Else, it was considered as a negative sample. Hence, TP and TN values characterized the General relativistic effects in quantum interference of positive and negative [118-164], pharmacophoric docking samples correctly identified. FP and FN Evading quantum mechanics may engineered a classical druggable subsystem within an atom merging quantum environment values denoted the number of positive and negative samples misidentified. By regulating the threshold, we were able to obtain the True Positive Rate (TPR) and False Positive Rate (FPR). Because AUC measure does not capture all aspects of the model's performance, adding the AUPR measure can more fully reflect the true performance of the model. The Hit Ratio (HR) evaluation indicator with high confidence was also used in this study by multiple clustering algorithms. Finally, the AUC Quantum correlations (Area Under Curve) value illustrating the similarity of the selected FDA cancer drugs through heterogeneous data integration of cluster relationships of drugs was acquired with no causal order based on known drug classifications by drawing the Receiver Operating Characteristic (ROC) curve. Moreover, this study contribution, we performed docking based virtual screening on three SARS-CoV-2 (the proteases Mpro and PLpro, and the spike glycoprotein) targets also used an in-house library of and investigational and experimental drugs approved FDA drugs (Area Under Precision-Recall Curve) to suggest potential compounds as the second evaluation indicator for reliable drug repositioning which may act as antivirals druggable scaffolds for recoring and remerging them into the SivirinavirTM drug design. In this work, we for the first time prepared a transmission analysis for anchored cancer drugs-Triptorelin-Halaven-Pazobanib-Votrient-Aloxi-Bosulif-Picato-Velcade-

Aliqopa-Xermelo-Nerlynx-Zytiga-Jevtana-Zykadia-Iclusig-Pomalyst-Folotyn-Dabrafenib-Cometriq-Mekinist-Varubi-Imbruvica-Akynzeo-Torisel-Cotellic-Stivarga-Venclexta Drugs $\{dr2, dr3, dr5\}$ that has been used in trials studying the treatment of different types of cancer, such as lymphoma, solid tumors, and Glioblastoma and performance parallel docking comparisons for allowing isolated (disconnected) drugs with other entanglement distribution schemes to be merged into the SivirinavirTM small molecule which binds inside the PDB:1XAK STRUCTURE OF THE SARS-CORONAVIRUS ORF7A ACCESSORY PROTEIN binding domains with some of 910339.768 Docking T.Energies (Table.4).

REFERENCES

1. Hui DS. Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). Clin Chest Med. 2017;38(1):71-86.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
3. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020;79:104212.
4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, *G* enomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74.
5. Luk HKH, Li X, Fung J, Lau SKP, Woo PCY. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019;71:21-30.
6. Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol. 2004;7(4):412-9.
7. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85-164.
8. Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol.2005;287:1-30.
9. Narayanan K, Huang C, Makino S. SARS coronavirus accessory proteins. Virus Res.2008;133(1):113-21.
10. Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J Virol. 2010;84(21):11418-28.
11. Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11-22.
12. Siu KL, Chan CP, Kok KH, Chiu-Yat Woo P, Jin DY. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol. 2014;11(2):141-9.
13. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69.
14. Liu DX, Yuan Q, Liao Y. Coronavirus envelope protein: a small membrane protein with multiple functions. Cell Mol Life Sci. 2007;64(16):2043-8.
15. Ruch TR, Machamer CE. The coronavirus E protein: assembly and beyond. Viruses. 2012;4(3):363-82.
16. McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991-3018.
17. Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH. The SARS coronavirus nucleocapsid protein--forms and functions. Antiviral Res. 2014;103:39-50.
18. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020.
19. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020.

20. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020.
21. Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. Cell. 2003;115(6):652-3.
22. Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, *S*ARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. Antiviral Res. 2014;101:122-30.
23. Graham RL, Sparks JS, Eckerle LD, Sims AC, Denison MR. SARS coronavirus replicase proteins in pathogenesis. Virus Res. 2008;133(1):88-100.
24. Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T, Ito N Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci U S A. 2006;103(34):12885-90.
25. Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng CT, Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471-9.
26. Tohya Y, Narayanan K, Kamitani W, Huang C, Lokugamage K, Makino S. Suppression of host gene expression by nsp1 proteins of group 2 bat coronaviruses. J Virol. 2009;83(10):5282-8.
27. Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL, Makino S. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011;7(12):e1002433.
28. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Res. 2018;149:58-74.
29. Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein Cell. 2014;5(5):369-81.
30. Baez-Santos YM, Mielech AM, Deng X, Baker S, Mesecar AD. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J Virol. 2014;88(21):12511-27.
31. Mielech AM, Deng X, Chen Y, Kindler E, Wheeler DL, Mesecar AD, et al. Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis. J Virol. 2015;89(9):4907-17.
32. Zhang W, Bailey-Elkin BA, Knaap RCM, Khare B, Dalebout TJ, Johnson GG Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants. PLoS Pathog. 2017;13(5):e1006372.
33. Baez-Santos YM, Barraza SJ, Wilson MW, Agius MP, Mielech AM, Davis NM ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem. 2014;57(6):2393-412.
34. Chou CY, Chien CH, Han YS, Prebanda MT, Hsieh HP, Turk B hiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol. 2008;75(8):1601-9.
35. Ghosh AK, Takayama J, Aubin Y, Ratia K, Chaudhuri R, Baez Y Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. J Med Chem. 2009;52(16):5228-40.
36. Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008;105(42):16119-24.
37. Zheng D, Chen G, Guo B, Cheng G, Tang H. PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res. 2008;18(11):1105-13.
38. Yin J, Niu C, Cherney MM, Zhang J, Huitema C, Eltis LD, et al. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase. J Mol Biol. 2007;371(4):1060-74.
39. Chou KC, Wei DQ, Zhong WZ. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun. 2003;308(1):148-51.
40. Muramatsu T, Kim YT, Nishii W, Terada T, Shirouzu M, Yokoyama S. Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CLpro) from its polyproteins. FEBS J. 2013;280(9):2002-13.

41. te Velthuis AJ, van den Worm SH, Snijder EJ. The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res. 2012;40(4):1737-47.
42. Xiao Y, Ma Q, Restle T, Shang W, Svergun DI, Ponnusamy R Nonstructural proteins 7 and 8 of feline coronavirus form a 2:1 heterotrimer that exhibits primer-independent RNA polymerase activity. J Virol. 2012;86(8):4444-54.
43. Zhai Y, Sun F, Li X, Pang H, Xu X, Bartlam M, et al. Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer. Nat Struct Mol Biol. 2005;12(11):980-6.
44. Imbert I, Guillemot JC, Bourhis JM, Bussetta C, Coutard B, Egloff MP A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J. 2006;25(20):4933-42.
45. te Velthuis AJ, Arnold JJ, Cameron CE, van den Worm SH, Snijder EJ. The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2010;38(1):203-14.
46. Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun. 2019;10(1):2342.
47. Seybert A, Hegyi A, Siddell SG, Ziebuhr J. The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5'-to-3' polarity. RNA. 2000;6(7):1056-68.
48. Ivanov KA, Thiel V, Dobbe JC, van der Meer Y, Snijder EJ, Ziebuhr J. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol. 2004;78(11):5619-32.
49. Lee NR, Kwon HM, Park K, Oh S, Jeong YJ, Kim DE. Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsP13. Nucleic Acids Res. 2010;38(21):7626-36.
50. Decroly E, Imbert I, Coutard B, Bouvet M, Selisko B, Alvarez K, et al. Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity. J Virol. 2008;82(16):8071-84.
51. Chen Y, Cai H, Pan J, Xiang N, Tien P, Ahola T Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci U S A. 2009;106(9):3484-9.
52. Wang Y, Sun Y, Wu A, Xu S, Pan R, Zeng C, et al. Coronavirus nsp10/nsp16 Methyltransferase Can Be Targeted by nsp10-Derived Peptide In Vitro and In Vivo To Reduce Replication and Pathogenesis. J Virol. 2015;89(16):8416-27.
53. Ogando NS, Ferron F, Decroly E, Canard B, Posthuma CC, Snijder EJ. The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity. Front Microbiol. 2019;10:1813.
54. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, et al. Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol Chem. 2014;289(37):25783-96.
55. Minskaia E, Hertzig T, Gorbalenya AE, Campanacci V, Cambillau C, Canard B, et al. Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A. 2006;103(13):5108-13.
56. Kang H, Bhardwaj K, Li Y, Palaninathan S, Sacchettini J, Guarino L, et al. Biochemical and genetic analyses of murine hepatitis virus Nsp15 endoribonuclease. J Virol. 2007;81(24):13587-97.
57. Bhardwaj K, Sun J, Holzenburg A, Guarino LA, Kao CC. RNA recognition and cleavage by the SARS coronavirus endoribonuclease. J Mol Biol. 2006;361(2):243-56.
58. Zhang L, Li L, Yan L, Ming Z, Jia Z, Lou Z, et al. Structural and Biochemical Characterization of Endoribonuclease Nsp15 Encoded by Middle East Respiratory Syndrome Coronavirus. J Virol. 2018;92(22).
59. Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol Inform. 2020.
60. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296-W303.
61. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D82.
62. Tchesnokov EP, Feng JY, Porter DP, Gotte M. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019;11(4).
63. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020:101615.

64. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2).
65. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020.
66. Kim JY. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020;35(7):e88.
67. Khot WY, Nadkar MY. The 2019 Novel Coronavirus Outbreak - A Global Threat. J Assoc Physicians India. 2020;68(3):67-71.
68. Zeng YM, Xu XL, He XQ, Tang SQ, Li Y, Huang YQ, et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia. Chin Med J (Engl). 2020.
69. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64-8.
70. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020.
71. Rebello KM, Andrade-Neto VV, Zuma AA, Motta MCM, Gomes CRB, de Souza MVN, et al. Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmania amazonensis promastigotes. Parasitology. 2018;145(10):1304-10.
72. Tatum H, Thuluvath PJ, Lawitz E, Martorell C, DeMicco M, Cohen S, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015;22(8):658-64.
73. Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21.
74. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, et al. Safety and activity of saquinavir in HIV infection. Lancet. 1995;345(8955):952-5.
75. Cook NJ, Li W, Berta D, Badaoui M, Ballandras-Colas A, Nans A, et al. Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science. 2020;367(6479):806-10.
76. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-14.
77. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020.
78. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.
79. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-61.
80. Van Meter R, Satoh T, Ladd TD, Munro WJ, Nemoto K (2013) Path selection for quantum repeater networks. Networking Science 3(1-4): 82-95.
81. Van Meter R, Ladd TD, Munro WJ, Nemoto K (2009) System Design for a Long-Line Quantum Repeater. IEEE/ACM Transactions on Networking 17: 1002-1013.
82. Lloyd S (2004) Infrastructure for the quantum Internet. ACM SIGCOMM Computer Communication Review 34:9-20.
83. Hanzo L (2002) Wireless Myths, realities and futures: From 3G/4G to optical and quantum Wireless. Proceedings of the IEEE 100: 1853- 1888.
84. Lloyd S, Mohseni M, Rebentrost P (2014) Quantum principal component analysis. Nature Physics. 10: 631.
85. Lloyd S (1997) Capacity of the noisy quantum channel. Physical Rev A 55: 1613-1622.

86. Gyongyosi L (2017) Quantum Imaging of High-Dimensional Hilbert Spaces with Radon Transform. International Journal of Circuit Theory and Applications 45(7): 1029-1046.
87. Yuan Z (2008) Experimental demonstration of a BDCZ quantum repeater node. Nature 454: 1098-1101.
88. Di Caro G, Ducatelle F, Gambardella LM (2005) AdHocNet: An Adaptive Nature-Inspired Algorithm for Routing in Mobile Ad-Hoc Networks. European Transactions on Telecommunications 16: 443-455.
89. Chou C (2007) Functional quantum nodes for entanglement distribution over scalable quantum networks. Science 316(5829): 1316-1320.
90. Kimble HJ (2008) The quantum Internet. Nature 453: 1023-1030.
91. Gyongyosi L (2014) The Correlation Conversion Property of Quantum Channels. Quantum Information Processing 13: 467-473.
92. Kok P (2007) Linear optical quantum computing with photonic qubits. Rev Mod Phys 79: 135-174.
93. Gisin N, Thew R (2007) Quantum Communication. Nature Photon 1: 165-171.
94. Enk SJ, Cirac JI, Zoller P (1998) Photonic channels for quantum communication. Science 279: 205-208.
95. Briegel HJ, Dur W, Cirac JI, Zoller P (1998) Quantum repeaters: the role of imperfect local operations in quantum communication. Phys Rev Lett 81:5932-5935.
96. Dur W, Briegel HJ, Cirac JI, Zoller P (1999) Quantum repeaters based on entanglement purification. Phys Rev A 59: 169-181.
97. Duan LM, Lukin MD, Cirac JI, Zoller P (2001) Long-distance quantum communication with atomic ensembles and linear optics. Nature 414: 413-418.
98. Van Loock P (2006) Hybrid quantum repeater using bright coherent light. Phys Rev Lett 96: 240501.
99. Zhao B, Chen ZB, Chen YA, Schmiedmayer J, Pan JW (2007) Robust creation of entanglement between remote memory qubits. Phys Rev Lett 98: 240502.
100. Goebel AM (2008) Multistage entanglement swapping. Phys Rev Lett 101: 080403.
101. Simon C (2007) Quantum repeaters with photon pair sources and multimode memories. Phys Rev Lett 98(9): 190503.
102. Tittel W (2009) Photon-echo quantum memory in solid state systems. Laser Photon Rev 4(2): 244-267.
103. Sangouard N, Dubessy R, Simon C (2009) Quantum repeaters based on single trapped ions. Phys Rev A 79(4): 042340.
104. Dur W, Briegel HJ (2007) Entanglement purification and quantum error correction. Rep Prog Phys 70: 1381-1424.
105. Munro WJ, Harrison KA, Stephens AM, Devitt SJ, Nemoto K (2010) From quantum multiplexing to high-performance quantum networking. Nature Photon 4: 792-796.
106. Sangouard N, Simon C, de Riedmatten H, Gisin N (2011) Quantum repeaters based on atomic ensembles and linear optics. Rev Mod Phys 83: 33-80.
107. Collins OA, Jenkins SD, Kuzmich A, Kennedy TA (2007) Multiplexed memory-insensitive quantum Repeaters. Phys Rev Lett 98: 060502.
108. Ralph TC, Hayes AJF, Gilchrist A (2005) Loss-Tolerant Optical Qubits. Phys Rev Lett 95: 100501.
109. Kwiat PG (1997) Hyper-entangled states. J Mod Opt 44(12): 2173- 2184.
110. Lo HK, Chau HF (1999) Unconditional security of quantum key distribution over arbitrarily long distances. Science. 283: 2050-2056.
111. Shor PW (1995) Scheme for reducing decoherence in quantum computer memory. Phys Rev A 52: R2493-R2496.
112. Bonabeau E, Dorigo M, Theraulaz G (1999) Swarm Intelligence: From natural to artificial systems, Oxford University Press, UK.
113. Meuleau N, Dorigo M (2002) Ant colony optimization and stochastic gradient descent. Artificial Life 8(2): 103-121.
114. Roth M, Wicker S (2003) Termite Ad-hoc networking with stigmergy. The Second Mediterranean Workshop on Ad-Hoc Networks pp. 2937- 2941.
115. Roth M, Wicker S (2005) Performance evaluation of pheromone update in swarm intelligent MANETs. Mobile and Wireless Communication Networks 335-346.
116. Simone G, Gadia D, Farup I, Rizzi A (2015) Ant colony for locality foraging in image enhancement. Multiobjective Swarm Intelligence. In Dehuri S, Jagadev AK, Panda M (eds). Springer, pp. 123-142

117.Roth M, Wicker S (2004) Asymptotic pheromone behavior in swarm intelligent MANETs: An analytical analysis of routing behavior. Mobile and Wireless Communications Networks, pp. 335-346.
118.Xiao YF, Gong Q (2016) Optical microcavity: from fundamental physics to functional photonics devices. Science Bulletin 61: 185-186.
119.Zhang W (2017) Quantum secure direct communication with quantum memory. Phys Rev Lett 118: 220501.
120.Biamonte J (2017) Quantum Machine Learning. Nature 549: 195-202.
121.Lloyd S, Mohseni M, Rebentrost P (2013) Quantum algorithms for supervised and unsupervised machine learning. arXiv: 1307.0411.
122.Dijkstra EW (1959) A note on two problems in connexion with graphs. Numerische Mathematik 1(1): 269-271.
123.Roth M (2005) Termite: A Swarm Intelligent Routing Algorithm for Mobile Wireless Ad-Hoc Networks. Ph.D. Thesis, Cornell University, New York, USA.
124.Jiang L (2009) Quantum repeater with encoding. Phys Rev A 79(3): 032325.
125.Sheng YB, Zhou L (2017) Distributed secure quantum machine learning. Science Bulletin 62(14): 1025-2019.
126.Aharonov Y, Susskind L (1967) Charge super selection rule. Phys Rev 155: 1428.
127.Aharonov Y, Susskind L (1967) Observability of the sign change of spinors under 2π rotations. Phys Rev 158: 1237.
128.Aharonov Y, Kaufherr T (1984) Quantum frames of reference. Phys Rev D 30(2): 368.
129.Bartlett SD, Rudolph T, Spekkens RW (2007) Reference frames, superselection rules and quantum information. Rev Mod Phys 79: 555.
130.Bartlett SD, Rudolph T, Spekkens RW, Turner PS (2009) Quantum communication using a bounded-size quantum reference frame. N J Phys 11: 063013.
131.Gour G, Spekkens RW (2008) The resource theory of quantum reference frames: manipulations and monotones. N J Phys 10(3): 033023.
132.Kitaev A, Mayers D, Preskill J (2004) Superselection rules and quantum protocols. Phys Rev A 69: 052326.
133.Palmer MC, Girelli F, Bartlett SD (2014) Changing quantum reference frames. Phys Rev A 89(5): 052121.
134.Bartlett SD, Rudolph T, Spekkens RW, Turner PS (2006) Degradation of a quantum reference frame. N J Phys 8(4): 58.
135.Smith ARH, Piani M, Mann RB (2016) Quantum reference frames associated with non-compact groups: The case of translations and boosts and the role of mass. Phys Rev A 94(1): 012333.
136.Poulin D, Yard J (2007) Dynamics of a quantum reference frame. N J Phys 9(5): 156.
137.Skotiniotis M, Toloui B, Durham IT, Sanders BC (2013) Quantum Frameness for CPT Symmetry. Phys Rev Lett 111(2): 020504.
138.Rovelli C (1991) Quantum reference systems. Class. Quantum Gravity 8(2): 317.
139.Poulin D (2006) Toy model for a relational formulation of quantum theory. Int J Theor Phys 45(7): 1189-1215.
140.Girelli F, Poulin D (2008) Quantum reference frames and deformed symmetries. Phys Rev D 77(10): 104012.
141.Miyadera T, Loveridge L, Busch P (2016) Approximating relational observables by absolute quantities: a quantum accuracy-size trade-off. J Phys. A 49(18): 185301.
142.Loveridge L, Busch P, Miyadera T (2017) Relativity of quantum states and observables. EPL (Europhys Lett) 117(4): 40004.
143.Loveridge L, Miyadera T, Busch P (2018) Symmetry, reference frames, and relational quantities in quantum mechanics. Found Phys 48: 135- 198.
144.Pienaar J (2016) A relational approach to quantum reference frames for spins. arXiv: 1601.07320.
145.Angelo RM, Brunner N, Popescu S, Short A, Skrzypczyk P (2011) Physics within a quantum reference frame. J Phys A 44(14): 145304.
146.Angelo RM, Ribeiro AD (2012) Kinematics and dynamics in noninertial quantum frames of reference. J Phys A 45(46): 465306.

147.Pereira ST, Angelo RM (2015) Galilei covariance and Einstein's equivalence principle in quantum reference frames. Phys Rev A 91(2): 022107.
148.Rovelli C (1996) Relational quantum mechanics. Int J Theor Phys 35: 1637-1678.
149.Brukner Č (2017) On the quantum measurement problem, In Quantum (Un) Speakables II, Springer International Publishing, pp. 95-117.
150.Greenberger DM (1979) Some remarks on the extended galilean transformation. Am J Phys 47(1): 35-38.
151.Katz BN, Blencowe MP, Schwab KC (2015) Mesoscopic mechanical resonators as quantum non-inertial reference frames. Phys Rev A 92(4): 042104.
152.Breuer T (1995) The impossibility of accurate state self-measurements. Philos. Sci 62(2): 197.
153.Dalla Chiara M (1977) Logical self-reference, set theoretical paradoxes and the measurement problem in quantum mechanics. J Philos Logic 6: 331-334.
154.Moshinsky M, Quesne C (1971) Linear canonical transformations and their unitary representations. J Math Phys 12(8): 1772-1780.
155.Anderson A (1994) Canonical transformations in quantum mechanics. Ann Phys. 232(2): 292-331.
156.Pikovski I, Zych M, Costa F, Brukner Č (2017) Time dilation in quantum systems and decoherence. N J Phys 19(2): 025011.
157.Peres A, Scudo PF, Terno DR (2002) Quantum entropy and special relativity. Phys Rev Lett 88(23): 230402.
158.Zych M, Costa F, Pikovski I, Brukner Č (2011) Quantum interferometric visibility as a witness of general relativistic proper time. Nat. Commun 2: 505.
159.Zych M, Pikovski I, Costa F, Brukner Č (2016) General relativistic effects in quantum interference of clocks. J Phys 723: 012044 IOP Publishing. Journal of Physics: Conference Series.
160.Pikovski I, Zych M, Costa F, Brukner Č (2015) Universal decoherence due to gravitational time dilation. Nat Phys 19(2): 668-672.
161.Møller CB (2017) Quantum back-action-evading measurement of motion in a negative mass reference frame. Nature 547: 191-195.
162.Polzik ES, Hammerer K (2015) Trajectories without quantum uncertainties. Ann Phys 527(1-2): A15-A20.
163.Hammerer K, Aspelmeyer M, Polzik ES, Zoller P (2009) Establishing einstein-poldosky-rosen channels between nano-mechanics and atomic ensembles. Phys Rev Lett 102: 020501.
164.Tsang M, Caves CM (2012) Evading quantum mechanics: Engineering a classical subsystem within a quantum environment. Phys Rev X 2(3): 031016.
165.Oreshkov O, Costa F, Brukner Č (2012) Quantum correlations with no causal order. Nat. Commun. 3: 1092.